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Chapter	  1:	  Review	  of	  Immune-­Mediated	  Hemolytic	  Anemia	  
	  
	  Immune-­‐mediated	   hemolytic	   anemia	   (IMHA)	   is	   a	   clinically	   important	   and	  potentially	  devastating	  disease	  in	  dogs,	  with	  a	  mortality	  rate	  that	  ranges	  from	  20%	  to	   70%1,2.	   The	   disease	   produces	   an	   acute,	   often	   severe,	   anemia,	  which	   frequently	  requires	   transfusion.	   IMHA	   also	   results	   in	   a	   systemic	   inflammatory	   state,	   which	  activates	   coagulation	   and	   may	   result	   in	   the	   development	   of	   thrombotic	  complications.	  Thrombosis	   is	  one	  of	   the	  major	  causes	  of	  death	   from	  IMHA,	   though	  financial	   demands	   from	   hospitalization	   and	   transfusion	   costs	   placing	   a	   significant	  burden	   on	   the	   client	   and	   may	   result	   in	   euthanasia.	   Therapy	   centers	   on	  glucocorticoid	  immunosuppression,	  as	  well	  as	  thrombophylaxis	  and	  supportive	  care	  (transfusions,	  enteral	  support).	  	  	   There	   is	   a	   substantial	   body	   of	   literature	   focused	   on	   canine	   IMHA,	   but	   the	  quality	  of	  the	  data	  lacks	  much	  external	  validity,	  as	  was	  recently	  demonstrated	  in	  a	  systematic	   review	   performed	   by	   Swann	   and	   Skelly3.	   The	   majority	   of	   the	   studies	  available	  are	  retrospective,	  so	  there	  exists	  substantial	  variability	   in	  the	  treatments	  received	   by	   the	   dogs	   and	   in	   the	   determinants	  measured.	   The	   prospective	   studies	  available	  often	  have	   low	  numbers	  of	   subjects,	   along	  with	  variability	   in	   treatments	  and	   measurements,	   as	   is	   the	   case	   in	   many	   veterinary	   clinical	   trials.	   An	   excellent	  review	  by	  Piek	  in	  20114	  discussed	  the	  clinical	  presentation	  and	  diagnostic	  workup	  of	  dogs	  with	  IMHA,	  as	  well	  as	  treatment	  recommendations.	  She	  concluded	  that	  the	  optimal	   method	   for	   improving	   prognosis	   in	   dogs	   with	   this	   disease	   is	   through	  collaborative	   efforts,	   standardization	   of	   testing,	   and	   the	   development	   of	   a	   scoring	  
 3 
 
system.	   Indeed,	   the	  development	  of	  registries	  and	  collaboration	  between	  hospitals	  is	  the	  next	  necessary	  step	  in	   improving	  outcome	  for	  this	  subset	  of	  canine	  patients.	  This	  chapter	  is	  a	  review	  of	  the	  current	  literature	  and	  understanding	  of	  the	  immune	  pathology,	   coagulation	   abnormalities,	   prognostic	   indicators,	   and	   therapies	   for	  canine	  IMHA.	  	  	  
Pathophysiology	  of	  Immune-­Mediated	  Hemolytic	  Anemia:	  	  IMHA	  is	  the	  most	  common	  cause	  of	  hemolytic	  anemia	  in	  dogs5.	  IMHA	  results	  from	   reduced	   self-­‐tolerance	   of	   red	   blood	   cell	   surface	   antigens6	   resulting	   in	  autoantibody	   formation	   and	   a	   type	   II	   hypersensitivity	   reaction.	   	   The	   majority	   of	  cases	   in	   the	   dog	   are	   considered	   to	   be	   idiopathic,	   or	   primary,	   although	   certain	  diseases	   such	   as	   underlying	   neoplasia	   or	   infectious	   causes	   such	   as	   parasitic	   or	  rickettsial	   diseases	   can	   elicit	   secondary	   IMHA.	   	   	   Certain	  drugs,	   such	   as	  penicillins,	  are	   also	   capable	   of	   eliciting	   a	   type	   II	   hypersensitivity	   response.	   	   Vaccination	   has	  been	  implicated	  as	  a	  trigger	  for	  the	  formation	  of	  autoantibodies,	  but	  there	  is	  limited	  data	  to	  support	  their	  role	  in	  IMHA7.	  	  IgG	  and	  IgM	  bind	  to	  the	  red	  blood	  cell	  surface	  through	  their	  variable	  regions	  (Fab)8.	   As	   a	   pentamer,	   IgM	   results	   in	   cross-­‐linking	   of	   red	   blood	   cells	   and	  autoagglutination	  and	  can	  fix	  complement.	  	  IgG,	  as	  a	  monomer,	  is	  conversely	  a	  poor	  activator	   of	   complement,	   as	   opposed	   to	   IgM,	   a	   pentamer.	   Complement	   is	   often	   a	  component	   of	   IgM-­‐mediated	   hemolytic	   anemia	   and	   can	   cause	   intravascular	  hemolysis.	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The	  specific	  immune	  dysfunction	  that	  leads	  to	  IMHA	  is	  currently	  unknown	  in	  dogs.	   It	   is	   unknown	   if	   primary	   IMHA	   is	   triggered	   by	   abnormal	   T	   cell	   activation,	  deficits	  in	  B	  cell	  tolerance,	  or	  whether	  there	  is	  a	  role	  for	  dendritic	  cells	  or	  regulatory	  T	  cells.	  There	  is	  evidence	  that	  dogs	  with	  IMHA	  have	  autoreactive	  T	  cells,	  supporting	  the	  role	  of	  T	  cells	  in	  triggering	  the	  autoimmune	  response9.	  	  Tan	  et	   al6	   evaluated	  cell	   surface	  antigens	   that	  are	   commonly	   found	   in	  dogs	  with	   IMHA.	   In	   12	   dogs	   with	   IMHA,	   they	   found	   a	   high	   prevalence	   of	   reactivity	   to	  antigens	   relating	   to	   oxidative	   stress	   and	   complement	   compared	   to	   dogs	   without	  IMHA.	   	   It	   is	   unknown,	   however,	   if	   these	   proteins	   are	   triggers	   or	   products	   of	   the	  disease6.	  Once	  autoreactive	  antibodies	  form	  to	  a	  specific	  self-­‐antigen,	  it	  is	  expected	  that	  epitope	  spreading	  to	  nearby	  or	  similar	  antigens	  will	  occur10.	  In	  humans,	  Band3	  on	  the	  red	  blood	  cell	  surface	  is	  the	  most	  common	  target	  in	  IMHA6	  but	  it	  is	  not	  known	  if	  Band3	  is	  the	  initial	  autoantibody	  target	  or	  a	  consequence	  of	  epitope	  spreading.	  	  Immunoglobulin	   (Ig)	   constant	   regions	   (Fc)	   are	   recognized	   by	   the	   Fc-­‐receptors	  on	  phagocytic	  cells	  of	  the	  mononuclear	  phagocytic	  system	  in	  the	  liver	  and	  spleen.	   	  The	  partial	  clearance	  of	  the	  red	  blood	  cell,	  via	  phagocytosis	  by	  the	  splenic	  macrophages	   or	   Kupffer	   cells	   of	   the	   liver,	   results	   in	   extravascular	   hemolysis	   and	  spherocyte	   formation.	   Spherocytes	   are	   visualized	   as	   smaller	   red	   blood	   cells	   on	   a	  blood	  smear	  with	  denser	  hemoglobin	  concentration	  and	  a	  lack	  of	  central	  pallor	  due	  to	  partial	  membrane	  removal.	   	  Although	  spherocytosis	   is	  considered	  a	  hallmark	  of	  IMHA,	   spherocytosis	   can	   occur	   in	   other	   conditions	   that	   cause	   red	   cell	  membrane	  damage	   such	   as	   neoplasia,	   rickettsial	   disease,	   or	   oxidative	   damage11.	   Spherocytes	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are	   often	   found	   in	   low	   numbers	   in	   those	   conditions,	   whereas	   they	   can	   be	  overwhelmingly	  present	  in	  IMHA.	  	  A	   systemic	   inflammatory	   response	   promotes	   progression	   of	   IMHA.	  Additional	   mononuclear	   cells	   which	   contribute	   to	   the	   phagocytosis	   of	   antibody-­‐bound	   red	   blood	   cells	   are	  mobilized	   from	   the	   bone	  marrow	   and	   are	   recruited	   to	  sites	  of	  inflammation.	  This	  migration	  of	  immune	  cells	  has	  been	  a	  source	  of	  study	  in	  as	   an	   attempt	   to	   further	   understand	   IMHA	   pathophysiology.	   MCP-­‐1	   (monocyte	  chemoattractant	   protein-­‐1)	   is	   a	   cytokine	   that	   originates	   from	   mononuclear	   and	  endothelial	  cells.	   	  A	  recent	  study	  demonstrated	  an	   increase	   in	  MCP-­‐1	   in	  dogs	  with	  IMHA12.	  Kjelgaard	  et	   al.13	   prospectively	  evaluated	  cytokines	  dogs	  with	   IMHA	  upon	  diagnosis	  of	  the	  disease.	  They	  demonstrated	  increased	  concentrations	  of	  cytokines	  IL-­‐2,	   IL-­‐4,	   IL-­‐10,	   and	   keratinocyte	   chemoattractant	   protein	   in	   dogs	   with	   IMHA	  relative	  to	  control	  dogs.	  IL-­‐4	  and	  IL-­‐10	  are	  cytokines	  that	  are	  involved	  in	  antibody	  production,	   and	   IL-­‐10	   is	   a	   marker	   of	   B	   cell	   activation	   and	   proliferation.	   	   These	  findings	  likely	  reflect	  the	  increased	  production	  of	  self	  antibodies.	  IL-­‐2	  is	  a	  CD4+	  Th-­‐related	  cytokine,	  which	  stimulates	  B	  cells	  to	  produce	  antibody.	  This	  study	  also	  found	  an	  increase	  in	  the	  expression	  of	  macrophage-­‐associated	  cytokines	  IL-­‐18	  and	  MCP-­‐1	  in	   nonsurvivors	   relative	   to	   survivors,	   indicating	   that	   macrophage/monocyte	  activation	  may	  have	  an	  important	  role	  in	  determining	  the	  outcome	  of	  IMHA	  patients.	  	  	  




The	  major	  cause	  of	  mortality	  from	  IMHA,	  the	  formation	  of	  thromboemboli,	  is	  poorly	   understood.	   Thromboemboli	   are	   classified	   as	   arterial	   or	   venous	   in	   origin.	  Arterial	  thrombi	  generally	  occur	  from	  activation	  of	  platelets	  in	  high-­‐flow	  conditions	  in	   arteries	   and	   arterioles,	   and	   are	   traditionally	   targeted	   via	   anti-­‐platelet	  medications,	  such	  as	  aspirin	  or	  clopidrogrel.	  Venous	  thrombi	  form	  in	  both	  veins	  and	  venules	   in	   low-­‐flow	   conditions	   and	   they	   are	   considered	   to	   be	   fibrin	   rich	   due	   to	  activation	   of	   coagulation	   factors	   triggering	   conversion	   of	   fibrinogen	   to	   fibrin.	  Therefore,	   they	   are	   traditionally	   targeted	  with	   anticoagulant	  medications	   such	   as	  heparin14.	  Thromboemboli	   are	   reported	   to	   occur	   commonly	   in	   dogs	   with	   IMHA	   in	  multiple	   studies,	   with	   ranges	   up	   to	   80%	   of	   dogs	   affected7,15,16,17.	   Pulmonary	  thromboemboli	  are	  the	  most	  common	  type	  of	  thromboemboli	  reported	  in	  dogs	  with	  IMHA.	   They	   have,	   however,	   been	   reported	   to	   occur	   in	   other	   locations,	   including	  cardiac	  tissue18,	  arterial	  sytems	  (such	  as	  splenic,	  renal,	   iliac,	  and	  mesenteric	  artery	  thrombi)	  and	  venous	  systems	  (portal	  vein,	  splenic	  vein,	  and	  vena	  cava)7,11,19,20.	  	  	  
Platelet	  Activation:	  	  Coagulation	   abnormalities	   in	   dogs	   with	   IMHA	   have	   been	   evaluated	  increasingly	   in	   the	   veterinary	   literature.	   	   Endothelial	   abnormalities,	   increased	  hypercoagulability,	  and	  abnormal	  blood	  flow	  (Virchow’s	  triad)	  have	  been	  explored	  as	   reasons	   for	   the	  high	  prevalence	  of	   thrombosis	   in	  dogs	  with	   IMHA.	   Importantly,	  dogs	   with	   IMHA	   have	   activated	   platelets	   relative	   to	   control	   dogs.	   Weiss	   and	  Brazzell21	  demonstrated	  that	  dogs	  with	  IMHA	  have	  increased	  P-­‐selectin	  expression	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on	   the	   surface	   of	   their	   platelets	   relative	   to	   healthy	   dogs.	   P-­‐selectin	   is	   inside	   the	  platelet’s	  alpha	  granule,	  and	  is	  expressed	  on	  the	  platelet	  surface	  upon	  activation.	  	  In	  their	  study,	  dogs	  with	  IMHA	  had	  P-­‐selectin	  expression	  that	  was	  8	  times	  higher	  than	  the	  expression	  in	  healthy	  control	  dogs.	  They	  also	  found	  that	  75%	  of	  dogs	  with	  IMHA	  had	  P-­‐selectin	  expression	  over	   the	   reference	   range	   for	   their	  population	  of	  healthy	  control	  dogs.	   	   The	   study	  by	  Ridyard	  et	   al22	   several	   years	   later	   corroborated	   these	  findings.	  Ridyard’s	  group	  found	  increases	  in	  fibrinogen-­‐platelet	  binding,	  P-­‐selectin,	  and	   platelet	   microparticles	   in	   dogs	   with	   IMHA	   compared	   to	   healthy	   dogs.	  	  Interestingly,	  they	  also	  found	  a	  relationship	  between	  platelet	  activation	  and	  severe	  thrombocytopenia,	   with	   higher	   platelet	   activation	   observed	   in	   the	   five	   severely	  thrombocytopenic	  dogs	   (n=14)	   in	   their	   study.	   In	   this	   group	  of	   fourteen	  dogs	  with	  IMHA,	   three	   did	   not	   survive	   to	   discharge	   and	   two	   of	   these	   dogs	   had	   suspect	  pulmonary	   thromboemboli.	   All	   three	   of	   these	   dogs	  were	   in	   the	   thrombocytopenic	  group.	  What	  is	  unknown	  at	  this	  point	  is	  whether	  the	  thrombocytopenia	  is	  a	  cause	  or	  effect	   of	   a	   prothrombotic	   state;	   is	   the	   platelet	   activation	   a	   result	   of	   systemic	  coagulation	   abnormalities	   or	   is	   it	   an	   effect	   of	   the	   inflammatory	   disease	   state	   and	  therefore	  causing	  a	  significant	  portion	  of	  the	  coagulation	  abnormalities?	  	  	  The	   plasma	  membrane	   of	   the	   platelet	   and	   the	   endothelial	   cell	   is	   normally	  asymmetrically	   charged,	   with	   anionic	   phospholipids	   such	   as	   phosphatidylserine	  (PS)	  on	  the	  inner	  leaflet.	  Damaged	  red	  blood	  cell	  membranes	  and	  activated	  platelets	  and	  platelet	  microparticles	  can	  lose	  this	  asymmetry.	  	  This	  results	  in	  exposure	  of	  PS	  to	  the	  outer	  surface	  of	  the	  cell.	  This	  can	  trigger	  coagulation	  by	  facilitating	  assembly	  of	   prothrombinase	   and	   tenase	   complexes,	   which	   are	   both	   critical	   steps	   in	   the	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coagulation	  cascade.	  Red	  blood	  cells	  expressing	  PS	  on	  their	  surfaces	  also	  bind	  to	  the	  macrophage-­‐PS	  receptors	  and	  induce	  phagocytosis.	  	  	  
Thrombocytopenia:	  	  Important	   aspects	   of	   coagulation	   that	   have	   been	   evaluated	   in	   dogs	   with	  IMHA	   include	   platelet	   number,	   tissue	   factor,	   and	   D-­‐dimers.	   Thrombocytopenia	   is	  common	   in	   dogs	   with	   IMHA7,11,23,24	   and	   in	   several	   studies	   thrombocytopenia	   has	  been	  identified	  as	  a	  poor	  prognostic	  indicator	  in	  dogs	  with	  IMHA2,7,16,22,24,25.	  A	  study	  by	  Orcutt	  et	  al18	  demonstrated	  that	  without	  concurrent	  DIC,	  there	  appears	  to	  be	  no	  increased	   risk	   of	   mortality	   with	   concurrent	   IMHA	   and	   thrombocytopenia;	   in	   that	  study	   nine	   of	   twelve	   dogs	   with	   IMHA	   and	   a	   platelet	   count	   of	   less	   than	   15,000	  cells/uL	  survived.	  The	  classification	  of	  the	  dogs	  in	  the	  Orcutt	  study	  as	  not	  having	  DIC	  is	  important;	  in	  many	  of	  the	  previous	  studies,	  other	  hemostatic	  abnormalities	  were	  present	  in	  the	  dogs	  with	  IMHA.	  These	  changes,	  often	  consistent	  with	  DIC,	  could	  have	  accounted	  for	  or	  contributed	  to	  the	  dogs’	  poorer	  prognosis	  if	  they	  reflected	  different	  pathologic	   processes	   or	   more	   fulminant	   disease.	   	   Other	   criteria	   of	   DIC	   that	   have	  been	   reported	   in	   dogs	   with	   IMHA	   include	   prolongation	   of	   coagulation	   times	   and	  elevated	   fibrin	   degradation	   products	   (FDPs)	   or	   D-­‐dimers.	   These	   findings	   in	   dogs	  with	   IMHA	   may	   be	   accounted	   for	   by	   a	   combination	   of	   increased	   procoagulant	  factors,	   the	   presence	   of	   free	   hemoglobin,	   decreased	   anticoagulant	   factors,	   and	  vasculitis19.	  	  	  	  
Tissue	  Factor:	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A	  study	  by	  Piek	  et	  al25	  evaluated	  the	  expression	  of	  intravascular	  tissue	  factor	  (TF)	  in	  dogs	  with	  IMHA	  and	  found	  it	  was	  elevated;	  TF	  initiates	  the	  intrinsic	  pathway	  of	  coagulation	  in	  the	  cell-­‐based	  model	  of	  coagulation.	  Interestingly,	  the	  TF	  levels	  did	  not	  have	  an	  association	  with	  survival	  of	  dogs	  with	  IMHA.	  	  	  
D-­dimers:	  	  D-­‐dimers	   are	   formed	   in	   the	   blood	   when	   thrombin	   cleaves	   fibrinogen,	  allowing	  Factor	  XIIIa,	  which	  is	  activated	  by	  thrombin,	  to	  cross-­‐link	  fibrin	  and	  form	  a	  stable	  clot.	  D-­‐dimers	  are	  therefore	  considered	  to	  be	  a	  measure	  of	  thrombin’s	  action	  on	   fibrinogen	   and	   are	   a	  marker	   for	   active	   coagulation	   and	   fibrinolysis.	   Dogs	  with	  IMHA	   often	   have	   elevated	   D-­‐dimers	   at	   the	   time	   of	   diagnosis22,26,27.	   D-­‐dimers	   are	  thought	   to	   be	   more	   sensitive	   and	   equally	   as	   specific	   as	   FDPs	   for	   thrombosis	   in	  dogs28.	  No	  studies	  to	  date	  have	  found	  a	  significant	  association	  between	  the	  elevation	  of	   D-­‐dimers	   and	   the	   increased	  morbidity	   or	   mortality	   from	   thromboembolism	   in	  dogs	  with	  IMHA.	  	  
Thromboelastography:	  	  Several	  groups	  have	  evaluated	  global	  coagulation	  in	  dogs	  with	  IMHA	  through	  thromboelastography	   (TEG),	   which	   gives	   an	   ex-­‐vivo	   assessment	   of	   overall	  coagulation	  status.	  One	  retrospective	  study29	  evaluated	  TEG	  tracings	  from	  dogs	  with	  IMHA.	  A	  few	  of	  these	  dogs	  were	  on	  some	  form	  of	  thrombophylactic	  medication.	  The	  authors	   found	   that	   33/39	   dogs	   had	   hypercoagulable	   TEG	   tracings.	   Interestingly,	  none	  of	   the	  6	  dogs	  with	  a	  normal	  coagulation	   index	  survived	  compared	  to	  56%	  of	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the	  dogs	  with	  hypercoagulable	  tracings.	  Unfortunately,	  we	  do	  not	  know	  the	  status	  of	  glucocorticoid	  therapy	  in	  this	  group	  of	  dogs.	  	  To	   account	   for	   the	   effects	   of	   glucocorticoid-­‐induced	   alterations	   on	   the	  TEG	  tracings,	  one	  study	  evaluated	  TEG	  upon	  admission	  in	  dogs	  with	  IMHA	  who	  had	  not	  received	   glucocorticoid	   therapy.	   The	   dogs	   with	   IMHA	   had	   multiple	   markers	   of	  hypercoagulability	   on	   their	   TEG	   tracings,	   including	   a	   high	   α-­‐angle,	   high	   MA,	   and	  high	   G27.	   The	   inherent	   confounder,	   however,	   when	   assessing	   dogs	   with	   IMHA	  through	  TEG,	   is	  that	  TEG	  tracings	  appear	  hypercoagulable	  in	  anemic	  dogs30,	  which	  makes	  it	  difficult	  to	  differentiate	  hypercoagulable	  tracings	  due	  to	  anemia	  from	  true	  hypercoagulability.	  	  Three	   studies	   have	   evaluated	   TEG	   in	   healthy	   dogs	   with	   glucocorticoid	  therapy,	   as	   glucocorticoids,	   the	   mainstay	   of	   treatment	   for	   dogs	   with	   IMHA,	   have	  been	  suspected	  to	  promote	  a	  hypercoagulable	  state	  themselves31,32,33.	  These	  studies	  found	   that	   administration	   of	   prednisone	   at	   immunosuppressive	   doses	   resulted	   in	  hypercoagulable	  TEG	  tracings.	  The	  addition	  of	  ultra	   low-­‐dose	  aspirin	   in	  two	  of	  the	  studies31,33,	  to	  mimic	  the	  effects	  of	  standard	  IMHA	  therapy,	  had	  no	  reduction	  in	  the	  hypercoagulable	   readings.	   Aspirin	   therapy	   alone	   did	   not	   affect	   TEG	   tracings	   to	  reduce	  the	  MA33.	  	  	  
Prognostic	  Factors:	  	  Many	  studies	  have	  evaluated	  dogs	  with	   IMHA	   to	   identify	   factors	  associated	  with	  survival.	  The	  majority	  of	  these	  studies	  are	  retrospective.	  Several	  findings	  have	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been	   inconsistent	   between	   studies,	   but	   there	   are	   some	   that	   have	   repeatedly	   been	  demonstrated	  to	  be	  abnormal	  in	  dogs	  that	  do	  not	  survive	  treatment.	  	  One	   study25	   found	   an	   association	   between	   increased	   mortality	   within	   the	  first	   two	   weeks	   of	   diagnosis	   and	   with	   the	   presence	   of	   icterus,	   increased	   BUN,	  leukocytosis,	   a	   left	   shift,	   and	   abnormalities	   in	   coagulation	   parameters	   including	  thrombocytopenia,	  increased	  coagulation	  times,	  and	  decreased	  fibrinogen.	  	  
Bilirubin:	  	  Hyperbilirubinemia	  has	  been	  documented	  in	  several	  studies	  to	  be	  associated	  with	  an	  increase	  in	  mortality	  2,3,7,8and	  thromboembolism1,7,20,35.	  Bilirubin	  >1.5	  ng/dL	  was	   associated	   with	   increased	   mortality	   in	   one	   study15	   and	   in	   another,	   bilirubin	  over	   5	   ng/dL	   was	   associated	   with	   an	   increased	   risk	   of	   thromboembolism7.	   The	  increased	   mortality	   associated	   with	   high	   bilirubin	   may	   be	   due	   to	   increased	  hemolysis,	  concurrent	  hepatic	  disease,	  more	  severe	  IgM	  and	  complement-­‐associated	  disease,	   or	   development	   of	   hepatic	   thromboses.	   Free	   hemoglobin	   may	   also	   bind	  nitric	   oxide,	   which	   normally	   inhibits	   platelet	   aggregation.	   Experimental	   data	   in	  humans	   suggests	   that	   hemolysis	   leads	   to	   the	   exposure	   of	   tissue	   factor	   (a	   potent	  procoagulant)	   on	   monocytes	   and	   endothelial	   cells	   and	   there	   is	   subsequent	  activation	  of	  coagulation23.	  	  	  
Alkaline	  Phosphatase:	  	  Elevated	  alkaline	  phosphatase	  (ALP),	  an	  enzyme	  associated	  with	  the	  plasma	  membrane	   of	   the	   hepatocytes	   and	   biliary	   epithelium	   in	   dogs,	   has	   also	   been	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associated	  with	   increased	  mortality15,	   and	   thromboembolism7	   in	  dogs	  with	   IMHA.	  This	  likely	  has	  similarities	  to	  the	  pathophysiology	  that	  results	  in	  hyperbilirubiemia’s	  association	  with	   increased	  mortality,	   as	   it	   is	   a	   sensitive	  marker	   for	   cholestasis.	   It	  also	   increases	   with	   prednisone	   therapy,	   which	   dogs	   with	   IMHA	   are	   almost	  invariably	  administered,	  but	  ALP	  values	  in	  dogs	  with	  IMHA	  rise	  acutely	  often	  prior	  to	   glucocorticoid	   administration.	   However,	   a	   synergistic	   effect	   on	   the	   canalicular	  hepatocytes	  or	  biliary	  epithelium	  from	  cholestasis	  and	  glucocorticoids	  resulting	   in	  hepatic	   dysfunction	   or	   microcirculatory	   disturbances	   cannot	   be	   completely	  excluded.	  	  	  
Blood	  Urea	  Nitrogen:	  	  Elevated	   blood	   urea	   nitrogen	   (BUN)	   has	   been	   found	   to	   be	   associated	  with	  increased	   mortality	   in	   a	   number	   of	   studies3,25,36.	   In	   a	   study	   by	   Swann	   et	   al3,	   the	  median	  BUN	  of	  dogs	   that	  survived	  was	  6.05	  mmol/L	  and	  the	  median	  BUN	  of	  dogs	  that	  did	  not	  survive	  was	  10	  mmol/L.	  It	  is	  unknown	  if	  this	  elevation	  in	  BUN	  is	  due	  to	  pre-­‐renal	   or	   renal	   azotemia,	   renal	   thrombosis,	   gastrointestinal	   compromise	   or	  ulceration,	  or	  a	  combination.	  	  	  
Lactate:	  	  Holahan	   explored	   the	   utility	   of	   lactate36	   as	   a	   point-­‐of-­‐care	   test	   and	   a	  relatively	   easy-­‐to-­‐measure	   prognostic	   marker.	   In	   84%	   of	   dogs	   with	   IMHA,	   the	  lactate	   levels	   were	   above	   the	   reference	   interval	   and	   lactate	   was	   higher	   in	  nonsurvivors	  compared	  to	  survivors.	  The	  authors	  reported	  that	  the	  dogs	  that	  had	  an	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elevated	  lactate	  that	  normalized	  within	  6	  hours	  survived.	  Lactate	  levels	  in	  this	  study	  were	   positively	   correlated	  with	  BUN	   and	  ALP,	   and	   inversely	   correlated	  with	   PCV.	  This	   is	   understandable,	   as	   decreased	   oxygen	  delivery	   due	   to	   anemia	  will	   increase	  anaerobic	  metabolism	  and	  lactate	   levels.	   In	  this	  study,	  a	   lactate	  of	  4.4mg/dL	  had	  a	  sensitivity	  of	  60%	  and	  a	  specificity	  of	  77%	  for	  mortality.	  	  As	  a	  result,	  its	  utility	  as	  a	  marker	   for	  mortality	   is	   not	   ideal,	   but	   it	  may	  be	  useful	   in	  monitoring	   endpoints	   of	  therapy	  or	  for	  being	  an	  indicator	  for	  the	  need	  of	  red	  blood	  cell	  transfusion.	  	  	  
Red	  Blood	  Cell	  Changes:	  	  Hematologic	  changes	  have	  been	  evaluated	   for	  associations	  with	   thrombosis	  and	  survival.	  Autoagglutination	  was	  associated	  with	  decreased	  short-­‐term	  survival	  in	  one	  retrospective	  study15,	  but	  the	  severity	  of	  autoagglutination	  was	  not	  assessed.	  Interestingly,	  spherocytosis	  was	  found	  to	  be	  negatively	  associated	  with	  death	  in	  one	  study25.	  	  	  	  
Platelets:	  	  Thrombocytopenia	  is	  a	  common	  finding	  in	  dogs	  with	  IMHA,	  with	  65-­‐70%	  of	  dogs	  with	   IMHA	   also	   having	   some	   degree	   of	   thrombocytopenia,	   and	   20%	  of	   dogs	  having	  platelet	  counts	  <50,000/ul7,11.	  Thrombocytopenia	  has	  been	  correlated	  with	  an	   increase	   in	  mortality7,15,22.	   As	  mentioned,	   a	   study	   evaluating	   dogs	  with	   severe	  thrombocytopenia	   (<15,000	   cells/uL)	   with	   concurrent	   IMHA	   and	   no	   evidence	   of	  disseminated	  intravascular	  coagulopathy	  (DIC)	  failed	  to	  find	  a	  significant	  increase	  in	  mortality	  in	  this	  patient	  population18.	  This	  suggests	  that	  other	  aspects	  of	  abnormal	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coagulation,	   potentially	   independent	   of	   platelets,	   may	   account	   for	   the	   increased	  mortality	   in	   thrombocytopenic	   dogs	   with	   IMHA.	   Other	   studies	   have	   evaluated	  platelet	   activation	   itself	   in	   dogs	   with	   IMHA.	   Ridyard	   et	   al22	   noted	   a	   strong	  correlation	   between	   increased	   markers	   of	   platelet	   activation	   and	   severe	  thrombocytopenia.	   As	   mentioned,	   dogs	   with	   IMHA	   had	   increased	   levels	   of	   P-­‐selectin,	   platelet-­‐derived	   microparticles	   (PMPs),	   and	   platelet-­‐fibrinogen	   binding	  relative	   to	  unaffected	  dogs.	   	  Weiss	  and	  Brazzell21	  also	   found	   increased	   levels	  of	  P-­‐selectin	  in	  dogs	  with	  IMHA,	  which	  is	  a	  marker	  of	  platelet	  and	  endothelial	  activation.	  	  The	   cause	   for	   thrombocytopenia	   is	   likely	  multifactorial	   in	  dogs	  with	   IMHA.	  The	   breakdown	   in	   self-­‐tolerance	   leads	   to	   red	   cell-­‐antibody	   complex	   formation,	  which	   results	   in	   red	   cell	   destruction	   and	   consumptive	   thrombocytopenia37.	   	   The	  general	  prothrombotic	  state	  in	  these	  dogs	  also	  may	  likely	  lead	  to	  additional	  platelet	  consumption.	   It	   is	   also	   possible	   that	   concurrent	   immune-­‐mediated	  thrombocytopenia	  is	  underdiagnosed.	  	  	  
White	  Blood	  Cell	  Changes:	  	  	   Leukocytosis,	  particularly	  a	  moderate	  to	  marked	  neutrophilia	  with	  a	  left	  shift	  and	   toxic	   change	   in	   neutrophils	   are	   other	   hematologic	   changes	   associated	  with	   a	  poor	   outome	   in	   dogs	   with	   IMHA2,13,25.	   In	   one	   study19,	   a	   moderate	   to	   marked	  leukocytosis	   was	   correlated	   with	   more	   severe	   postmortem	   lesions	   in	   dogs,	   the	  majority	  of	   these	  being	   ischemic	   lesions	  secondary	   to	  hypoxic	   tissue	  damage	   from	  anemia	   or	   thromboembolism.	   Leukocytosis	   is	   considered	   to	   be	   a	   reflection	   of	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moderate	  to	  marked	  tissue	  damage.	  Bands	  have	  been	  implicated	  in	  several	  studies	  
2,19,	  and	  may	  represent	  systemic	  inflammation	  or	  marrow	  hypoxic	  damage.	  	  	   Other	   markers	   of	   coagulation	   have	   been	   evaluated	   in	   dogs	   with	   IMHA,	  including	   coagulation	   time	   testing,	   fibrinogen	   levels,	   and	   antithrombin	   III	   levels.	  Increased	   activated	   partial	   thromboplastin	   time	   (aPTT)	   has	   been	   associated	  with	  increased	  mortality	   in	   several	   studies15,25,38.	   Increased	  prothrombin	   time	   (PT)	  has	  also	  been	  demonstrated	  to	  be	  associated	  with	  a	  poor	  outcome	  in	  one	  study2.	  These	  findings	   are	   often	   concurrent	   with	   other	   markers	   of	   inflammation.	   Kuzi	   et	   al38	  demonstrated	   that	   elevated	   aPTT	  was	   found	   concurrently	  with	   elevated	   bilirubin,	  low	  antithrombin	  levels,	  hypoalbuminemia,	  and	  leukocytosis38.	  	  
	  
Antithrombin	  III:	  Antithrombin	   III	   (ATIII)	   has	   been	   of	   clinical	   interest	   in	   hypercoagulable	  diseases.	  ATIII	   is	  a	   liver-­‐generated	  large	  serine	  protease	   inhibitor,	  which	  is	  critical	  for	  regulating	  coagulation	  by	  inactivating	  Factors	  X,	  II,	  VIIa,	  and	  plasmin.	  It	  accounts	  for	  about	  80%	  of	  the	  total	  inhibitory	  effect	  of	  plasma	  on	  coagulation38	  .	  ATIII	  is	  also	  important	   for	   the	   appropriate	   function	   of	   heparin.	   Heparin	   is	   used	   as	  antithrombotic	   therapy	   for	  dogs	  with	   IMHA	  (below).	  Antithrombin	   III	  significantly	  increases	   in	   activity	   when	   interacting	   with	   endogenous	   heparan	   sulfate	  proteoglycans39,40.	   ATIII	   can	   be	   decreased	   in	   several	   disease	   states	   due	   to	   loss,	  production	   deficiencies,	   or	   increased	   degradation,	   which	   can	   lead	   to	   a	  hypercoagulable	  state.	  Kuzi	  et	  al38	  retrospectively	  evaluated	   the	   incidence	  of	  ATIII	  abnormalities	  in	  20	  dogs	  with	  IMHA	  and	  found	  decreased	  ATIII	  levels	  in	  10	  of	  them.	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This	   study	   found	   an	   increased	   odds	   ratio	   for	   mortality,	   in	   all	   dogs	   with	  hypoantithrombinemia,	   when	   ATIII	   levels	  were	   less	   than	   60%	   (OR	   9.9)	   and	   30%	  (OR	  14.7).	  However,	  within	  the	  subset	  of	  dogs	  with	  IMHA,	   low	  ATIII	   levels	  did	  not	  result	   in	   an	   increase	   in	   the	   odds	   of	   mortality.	   A	   study	   by	   Scott-­‐Moncreiff	   et	   al11	  demonstrated	   that	  76%	  of	   the	  20	  dogs	  evaluated	  with	   IMHA	  had	   low	  ATIII	   levels.	  This	  study	  evaluated	  the	  risk	  of	  low	  ATIII	  levels	  for	  thromboembolic	  complications	  and	  it	  could	  not	  identify	  a	  relationship	  between	  the	  two	  variables.	  	  	  
Fibrinogen:	  	  Fibrinogen	   levels	   have	   been	   evaluated	   in	   IMHA	  patients	   in	   several	   studies.	  Fibrinogen	   is	   a	   soluble	   plasma	   protein	   that	   is	   converted	   to	   fibrin	   by	   thrombin.	  Thrombin	   converts	   fibrinogen	   to	   an	   insoluble	   form,	   and	   it	   is	   then	   cross-­‐linked	  by	  factor	  XIII.	  Fibrinogen	  is	  used	  diagnostically	  as	  a	  marker	  of	  inflammation,	  as	  it	  is	  an	  acute-­‐phase	  protein	  and	  marker	  of	  prothrombotic	  state.	  Fibrinogen	  is	  often	  found	  to	  be	   elevated	   in	   dogs	  with	   IMHA19,24,25,27.	   The	   elevation	   in	   this	   acute	   phase	   protein	  also	  has	  implications	  for	  anticoagulant	  therapy.	  	  	  
Anticoagulant	  Therapy:	  	  As	  thromboembolic	  complications	  can	  be	  devastating	  in	  patients	  with	  IMHA,	  and	  dogs	  with	  IMHA	  are	  hypercoagulable,	  it	  is	  critical	  to	  employ	  aggressive,	  effective	  antithrombotic	   therapy	   in	   these	   patients.	   Currently,	   different	   methods	   for	  anticoagulant	   therapy	   are	   used.	   The	  most	   common	   are	   anti-­‐platelet	   therapy	  with	  aspirin	   or	   clopidogrel	   or	   prolongation	   of	   the	   coagulation	   cascade	   with	  
 17 
 
unfractionated	  or	  low	  molecular-­‐weight	  heparin.	  Preferences	  for	  the	  use	  of	  one	  or	  a	  combination	  of	  these	  therapies	  in	  treatment	  of	  IMHA	  vary	  among	  veterinarians,	  and	  are	   based	   on	   personal	   experience,	   ease	   of	   administration,	   cost,	   and	   monitoring	  requirements.	  As	  there	  are	  both	  venous	  and	  arterial	  thromboses	  in	  these	  dogs,	  it	  is	  difficult	   to	   say	   that	   one	   method	   of	   anticoagulant	   therapy	   (targeting	   platelets	   or	  coagulation	  factors)	  is	  superior	  to	  another.	  	  	  




	   Clopidogrel	   is	   an	   irreversible	   inhibitor	   of	   the	   ADP-­‐receptor	   P2Y12	   on	   the	  platelet	   membrane,	   which	   is	   an	   important	   receptor	   for	   triggering	   platelet	  aggregation.	   It	   is	   may	   be	   used	   in	   conjunction	   with	   aspirin	   in	   some	   conditions	   in	  humans.	   There	   has	   been	   one	   controlled,	   open-­‐label	   study	   in	   dogs44	   evaluating	  clopidogrel	   and	   aspirin	   alone	   or	   together	   in	   dogs	  with	   IMHA.	   This	   study	   failed	   to	  note	  any	  differences	  between	  survival	  or	  thrombotic	  complications	  among	  the	  three	  groups,	  leading	  the	  authors	  to	  conclude	  that	  clopidogrel	  is	  not	  superior	  to	  aspirin.	  It	  may,	   however,	   be	   a	   safe	   and	   useful	   alternative,	   particularly	   in	   dogs	   with	  gastrointestinal	  dysfunction.	  	  	  
Heparin:	  	  	   Heparin	   has	   been	  widely	   used	   in	   dogs	   with	   IMHA.	   Unfractionated	   heparin	  facilitates	  antithrombin-­‐mediated	  inactivation	  of	  thrombin	  and	  factor	  Xa,	  inactivates	  factors	  IXa,	  XIa,	  VIIa,	  and	  XIIa,	  and	  increases	  the	  release	  of	  tissue	  factor	  plasminogen	  inhibitor	   from	   endothelial	   cells.	   Heparin	   can	   also	   inhibit	   the	   binding	   of	  phosphatidylserine	   to	   thrombospondin	   on	   endothelial	   cells,	   which	   reduces	   the	  prothombinase	  and	  tenase	  complex	  formation.	  	  	   Unfractionated	   heparin,	   however,	   requires	   appropriate	   monitoring.	  Historically,	   this	   has	   been	   through	   monitoring	   of	   aPTT;	   however,	   there	   is	  considerable	   variability	   in	   the	   reagents	   used	   for	   aPTT	  monitoring	  which	   leads	   to	  	  erratic	   results	   for	   heparin	   targets41. Additionally, the aPTT assay is affected by a 
variety of factors, including hyperfibrinogenemia, which is present in many dogs with 
IMHA (above). Increased circulating factor VIII levels can shorten aPTT times. 
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Currently, the more ideal test for monitoring and adjusting unfractionated heparin doses 
are levels of anti-factor Xa, since this is a direct target of unfractionated heparin. Breuhl 
et al24 evaluated the effects of unfractionated heparin on anti-Xa levels in dogs with 
IMHA, using standard doses of heparin (300U/kg q 6 hours). In this study, less than 50% 
of dogs achieved target ranges of anti-Xa within the first 40 hours of therapy. This study 
demonstrated that standard doses of heparin were not optimal for dogs with IMHA. Since 
many dogs have elevated fibrinogen, and fibrinogen and other acute phase proteins bind 
to heparin preferentially, it is entirely possible that dogs with IMHA require higher doses. 
Studies in humans have demonstrated that subtherapeutic heparin can, in fact, increase 
the risk of thromboembolism in certain diseases 41,46,47.	  Helmond et al48 compared dogs 
with standard dose heparin therapy to dogs who received heparin adjusted to achieve 
anti-Xa levels within the therapeutic target (0.35-0.7 U/mL). In this study, 7/8 dogs with 
individually adjusted heparin survived (for how long?), with one dog in the treatment 
group succumbing to thromboembolic complications. In the standard dose group, 1/7 
survived, and 5 of the 6 dogs that did not survive had documented thrombotic 
complications. Interestingly, this study also demonstrated that the trough anti-Xa levels 
were subtherapeutic, which may indicate that these dogs require more frequent heparin 
dosing. Additionally, heparin may not be as effective when antithrombin levels are low 
(below 60%)38, which is a common laboratory finding in dogs with IMHA (above).  
Low molecular weight heparin differs from unfractionated heparin in that it is 
comprised of smaller heparin molecules, as opposed to a mixture of small and larger 
molecules. Low molecular weight heparin cannot be monitored by aPTT levels, since the 
smaller heparin molecules are not large enough to inhibit thrombin when complexed to 
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antithrombin. One study examined dalteparin in dogs, and the study found that it	  failed	  to	  increase	   anti-­‐Xa	   levels	   from	   baseline49.	   Low	   molecular	   weight	   heparin	   may,	  however,	   be	   a	   safe	   alternative	   to	   unfractionated	   heparin,	   particularly	   if	  unfractionated	  heparin	  has	  a	  short	  half-­‐life	  in	  dogs	  with	  IMHA.	   
	  
Immune-­Modulatory	  and	  Adjunctive	  Therapies:	  	  The	  mainstay	  of	   therapy	   for	   IMHA	   is	   immunosuppression	  with	  prednisone.	  However,	   because	   prednisone	   has	   considerable	   side	   effects,	   it	   may	   contribute	   to	  thromboembolic	   tendencies	   (above),	   and	  may	   not	   be	   sufficient	   alone	   to	   suppress	  IMHA.	   	  Second-­‐line	  immunosupressives	  and	  other	  therapies	  have	  been	  explored	  in	  IMHA	  patients.	  	  	  
Azathioprine	  and	  Cyclosporine:	  	  Azathioprine	   and	   cyclosporine	   have	   been	   evaluated	   retrospectively	   in	  several	  studies3,25.	  Azathioprine	  is	  a	  purine	  synthesis	  inhibitor,	  which	  inhibits	  T	  cell	  responses50.	  Side	  effects	  are	  common	  with	  azathioprine	  and	  include	  hepatotoxicity	  and	  marrow	  suppression	  due	   to	   the	  mercaptopurine	  metabolite.	  Cyclosporine	   is	   a	  calcineurin	   inhibitor,	  which	   also	   suppresses	  T-­‐cell	   function50.	   Cyclosporine	   can	  be	  cost-­‐prohibitive	  in	  large	  dogs	  	  and	  it	  can	  result	  in	  gastrointestinal	  upset	  and	  gingival	  hyperplasia.	   In	  one	  study3,	   there	  was	  an	  effect	  of	   treatment	  on	  survival.	  Dogs	  who	  received	   azathioprine	   and	  prednisone	  or	  prednisone	   alone	  had	   improved	   survival	  relative	   to	   dogs	  who	   received	   cyclosporine	   and	   prednisone.	   However,	   it	  was	   also	  noted	   in	   this	   study	   that	   the	   dogs	   receiving	   prednisone	   alone	   had	   lower	   bilirubin	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levels	  and	  received	  fewer	  blood	  transfusions	  than	  dogs	  in	  the	  other	  groups,	  and	  the	  dog	  numbers	  in	  each	  group	  were	  too	  small	  to	  draw	  significant	  conclusions.	  Another	  study25	   retrospectively	   evaluated	   a	   large	   number	   of	   dogs	   with	   IMHA	   who	   either	  received	  prednisone	  or	  prednisone	  and	  azathioprine.	  There	  was	  no	  difference	  in	  the	  survival	  between	  these	  two	  groups	  of	  dogs.	  	  	  
Mycophenolate	  mofetil:	  	  One	   paper51	   has	   examined	   mycophenolate	   mofetil	   in	   dogs	   with	   IMHA.	  Mycophenolate	  is	  appealing	  as	  an	  adjunct	  immunosuppressive,	  since	  its	  mechanism	  of	   action	   as	   a	   purine	  metabolite	   inhibitor	   is	   similar	   to	   azathioprine,	   but	   the	   side	  effects	  are	  considered	  to	  be	  more	  tolerable	  and	  tend	  to	  be	  restricted	  to	  large-­‐bowel	  diarrhea.	  This	  paper	  evaluated	  five	  dogs	  with	  IMHA	  who	  received	  mycophenolate	  at	  10-­‐15	   mg/kg	   three	   times	   daily,	   which	   is	   higher	   than	   the	   doses	   currently	  recommended50.	  In	  this	  study,	  one	  dog	  died	  at	  day	  20	  due	  to	  progressive	  IMHA,	  and	  one	   dog	   died	   due	   to	   mycophenolate-­‐induced	   gastrointestinal	   toxicity.	  Mycophenolate	  at	  a	  lower	  dose	  warrants	  further	  evaluation	  in	  dogs	  with	  IMHA.	  	  	  
Human	  Intravenous	  Immunoglobulin:	  	  Human	   intravenous	   immunoglobulin	   (hIVIg)	   has	   also	   been	   evaluated	   in	  several,	   mostly	   retrospective,	   studies	   as	   a	   therapy	   for	   dogs	   with	   IMHA11,26,52,53.	  Human	   IVIg	  modulates	   the	   expression	   and	   function	  of	   Fc	   receptors	  on	  phagocytic	  cells,	   possibly	   via	   sialylation	   of	   the	   receptors54	   and	   interferes	   with	   B	   and	   T	   cell	  function,	   as	   well	   as	   complement.	   Many	   of	   the	   studies	   are	   inconclusive,	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demonstrating	  no	  significant	  adverse	  effects	  but	  no	  clear	  benefit	  in	  terms	  of	  survival	  or	  complications.	  A	  prospective	  study26	  evaluated	  hIVIg	  as	  an	   initial	   therapy	   in	  28	  dogs	   with	   IMHA.	   This	   study	   did	   not	   seem	   to	   demonstrate	   any	   significant	  improvement	   in	   initial	   response	   to	   therapy	   with	   steroids	   or	   shortening	   of	   the	  treatment	  time.	  	  	  
Splenectomy:	  	  Finally,	   splenectomy	   has	   been	   examined	   in	   dogs	   with	   IMHA55.	   This	   study	  evaluated	   ten	   cases	   of	   dogs	   with	   IMHA	  who	   had	   undergone	   splenectomy,	   on	   the	  basis	  that	  humans	  with	  IMHA	  are	  often	  splenectomized	  with	  good	  results.	  Humans	  who	  have	  warm	   immune-­‐mediated	  hemolytic	  anemia,	  which	   is	   the	  closest	  disease	  that	   parallels	   the	   canine	   condition,	   do	   respond	   initially	   to	   splenectomy	   but	   may	  relapse;	  overall	   it	   is	  a	  promising	  treatment	  for	  them56.	  Horgan55	  found	  that	  nine	  of	  ten	  dogs	  who	  received	  prednisone	  as	  well	  as	  splenectomy	  within	  4	  days	  of	  initiating	  treatment	  survived,	  with	  one	  dog	  succumbing	  perioperatively.	  They	  did	  not	  report	  the	   thromboembolic	   complications	   in	   these	   dogs.	   However,	   despite	   the	   good	  outcomes	   in	   these	   dogs,	   splenectomy	   is	   not	   a	   popular	   therapeutic	   intervention,	  likely	  due	  to	  the	  morbidity,	  risk	  for	  thrombosis,	  and	  cost	  associated	  with	  surgery.	  	  	  
Conclusions	  and	  Future	  Directions:	  	  Although	   the	   veterinary	   community	   has	   come	   far	   in	   its	   understanding	   of	  canine	   IMHA,	   there	  remains	  a	  great	  deal	   to	  evaluate	  and	  consider.	  There	  has	  been	  considerable	  effort	  to	  determine	  both	  the	  specific	  pathophysiology	  of	  the	  disease	  as	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Chapter	  2:	  Comparison	  of	  Individually-­Adjusted	  Heparin	  Versus	  Ultra	  Low-­
Dose	  Aspirin	  for	  Prevention	  of	  Thromboemboli	  in	  Immune-­Mediated	  
Hemolytic	  Anemia	  in	  Dogs	  
	  
Abstract:	  	  Immune-­‐mediated	   hemolytic	   anemia	   is	   a	   common	   cause	   of	   anemia	   in	   dogs,	   and	  results	   in	   considerable	   mortality	   and	   significant	   thromboembolic	   risk.	   Ultra-­‐low	  dose	   aspirin	   (ULDA)	   is	   most	   commonly	   used	   to	   try	   and	   prevent	   thrombosis,	   but	  individually-­‐adjusted	   heparin	   (IAD),	   based	   on	   anti-­‐factor	   Xa	   levels,	   may	   be	   more	  effective.	   Dogs	  were	   randomized	   to	   receive	  ULDA	   and	   a	   placebo	   injection,	   or	   IAD	  injections	  and	  a	  placebo	  capsule.	  Time	  to	  thrombosis	  or	  death	  up	  to	  180	  days	  was	  recorded.	   As	   the	   sample	   size	   was	   small	   at	   the	   time	   of	   interim	   analysis	   (n=22),	  additional	   dogs	   were	   included	   from	   a	   previous	   trial	   (IAD)	   or	   from	   review	   of	   the	  medical	  records	  (ULDA),	  resulting	  in	  40	  subjects.	  There	  were	  no	  differences	  in	  the	  baseline	  laboratory	  values	  between	  the	  two	  groups,	  although	  the	  total	  bilirubin	  was	  higher	   in	   the	  ULDA	  group	   than	   the	   IAD	  group	  (p=0.1).	  There	  was	  no	  difference	   in	  survival	  to	  180	  days	  (p=0.18),	  but	  the	  difference	  in	  thromboembolic	  complications	  approached	  significance	   (p=0.07),	  with	  dogs	   in	   the	   IAD	  group	   less	   likely	   to	  have	  a	  thrombotic	   complication.	   Increased	   total	   bilirubin	   (p=0.06),	   aPTT	   (p=0.04),	   and	  BUN	   (p=0.04)	   at	   admission	  were	  associated	  with	   an	   increased	   risk	  of	   thrombosis.	  IAD	   in	   dogs	   warrants	   further	   investigation	   to	   prevent	   thromboembolic	  complications	  in	  dogs	  with	  IMHA	  over	  ULDA.	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Introduction:	  Immune-­‐mediated	   hemolytic	   anemia	   (IMHA)	   is	   an	   autoimmune	   disease	  characterized	  by	  autoreactive	  self	  antibodies	  targeting	  the	  surface	  of	  the	  red	  blood	  cells	  and	  marking	   them	  for	  destruction.	  This	  disease	   is	  an	   important	  and	  common	  cause	  of	  morbidity	  and	  mortality	   in	  dogs.	   IMHA	  can	  result	  as	  a	   secondary	  process	  from	  the	  presence	  of	  cancer,	  infection,	  or	  exposure	  to	  certain	  medications,	  although	  the	  majority	  of	  cases	  of	  IMHA	  in	  dogs	  are	  considered	  to	  be	  primary.	  	  Currently,	  prednisone	  is	  the	  only	  medication	  that	  has	  been	  shown	  to	  improve	  survival	   in	   dogs	   with	   IMHA.	   Other	   immunosuppressants	   have	   been	   evaluated	   in	  addition	   to	   prednisone,	   but	   none	   have	   shown	   clear	   benefit,	   and	   most	   have	   been	  evaluated	  in	  retrospective	  cohort	  studies.	  Prednisone,	  although	  effective,	  can	  result	  in	  considerable	  morbidity	  in	  dogs,	   including	  iatrogenic	  hypercortisolism,	  increased	  risk	   for	   infection	   due	   to	   chronic	   immunosuppression,	   and	   increased	   tendency	   for	  thromboembolism.	  	  Thromboembolism	   is	  an	   important	  and	  common	  complication	   in	  dogs	  with	  IMHA,	  and	  these	  dogs	  are	  noted	  to	  be	  hypercoagulable	  prior	  to	  prednisone	  therapy7,	  
11,	   15,	   19,	   20,	   27,	   57.	   Thromboembolism	   is	   thought	   to	  be	  multifactorial	   in	   origin	   in	   this	  population	  of	  dogs;	  systemic	   inflammation,	  activated	  platelets21,	  agglutination,	  and	  hemolysis	   are	   all	   thought	   to	   be	   components	   of	   the	   hypercoagulable	   state	   IMHA	  produces.	   Dogs	   with	   IMHA	   tend	   to	   have	   several	   markers	   of	   coagulation	  abnormalities;	   many	   have	   increased	   d-­‐dimers,	   prolonged	   coagulation	   times,	   and	  platelet	  abnormalities23,	   26.	  Survival	  of	  this	  disease	  in	  the	  canine	  population	  ranges	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from	  30%	  to	  80%,	  with	  thromboembolic	  complications	  a	  leading	  cause	  of	  mortality,	  especially	  within	  the	  first	  several	  weeks	  of	  treatment1,	  2,	  7.	  Currently,	  no	  reliable	  method	  of	  anticoagulation	  exists	   for	  dogs	  with	   IMHA.	  Commonly	   accepted	   as	   standard	   of	   care	   is	   ultra	   low-­‐dose	   aspirin	   (ULDA);	   this	  became	  standard	  therapy	  after	  retrospective	  data	  assessing	  outcome	  in	  a	  population	  of	   dogs	  with	   IMHA	  was	   evaluated,	   and	  noted	   improved	   survival	   in	   dogs	   receiving	  ULDA	   therapy	   over	   standard-­‐dose	   heparin	   or	   no	   antithrombotic	   therapy15.	   	   Since	  that	   study,	   however,	   new	   data	   has	   been	   generated	   demonstrating	   that	   ULDA	  therapy	  may	  be	  unreliable	  in	  dogs,	  and	  may	  not	  inhibit	  platelet	  activity	  to	  the	  extent	  necessary	  to	  prevent	  thromboembolism43.	  A	  subsequent	  study	  looking	  at	  dogs	  with	  IMHA	  demonstrated	   that	  ULDA	   therapy	  did	  not	   reliably	   inhibit	   platelet	   activity	   in	  that	  population58.	  Clopidogrel,	  an	   irreversible	   inhibitor	  of	  the	  ADP-­‐receptor	  P2Y12	  on	  the	  platelet,	  was	  shown	  in	  one	  study	  to	  be	  no	  better	  than	  ULDA	  therapy44.	  	  Heparin	   therapy	   is	   also	   considered	   to	   be	   ineffective	   in	   dogs	   with	   IMHA24.	  Targeting	   heparin	   therapy	   to	   achieve	   a	   certain	   level	   of	   inhibition	   of	   Factor	   Xa	   is	  considered	  to	  be	  the	  most	  reliable	  way	  to	  prevent	  thromboembolism,	  and	  an	  anti-­‐Xa	  assay	   has	   been	   validated	   for	   use	   in	   dogs.	   One	   study	   demonstrated	   that	   300	  U/kg	  heparin	  in	  dogs	  with	  IMHA	  was	  not	  sufficient	  to	  achieve	  appropriate	  anti-­‐Xa	  levels24	  and	   a	   second	   study	   compared	   standard-­‐dose	   heparin	   therapy	   to	   individually-­‐adjusted	  therapy	  (IAD)	  that	  targeted	  anti-­‐Xa	  levels	  within	  the	  therapeutic	  range	  48.	  This	   study	   demonstrated	   significant	   improvement	   in	   survival	   in	   the	   dogs	   who	  received	   individually-­‐adjusted	   therapy	   as	   opposed	   to	   standard	   dose	   heparin	  therapy.	  The	  data	  from	  the	  dogs	  with	  individually-­‐adjusted	  heparin	  was	  promising,	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and	   therefore	   needed	   to	   be	   compared	   to	   current	   standard	   therapy	   of	   ULDA.	   The	  purpose	  of	   this	   study	  was	   to	  determine	   the	  effect	  of	   individually-­‐adjusted	  heparin	  (IAD)	   therapy	   in	   dogs	   compared	   to	   ULDA	   in	   preventing	   thrombosis	   in	   dogs	  with	  IMHA.	  	  
	  
Materials	  and	  Methods:	  	  
Study	  Design:	  This	   study	   was	   a	   prospective,	   randomized,	   double-­‐blinded	   placebo	  controlled	  clinical	  trial.	  The	  individually	  adjusted	  dose	  (IAD)	  group	  of	  dogs	  received	  unfractionated	  heparin	  (UH)	  to	  a	  target	  plasma	  concentration	  of	  0.35-­‐0.7	  U/mL.	  The	  low-­‐dose	  aspirin	  group	  (LDA)	  received	  aspirin	  at	  0.5	  mg/kg/day	  PO;	  dogs	  who	  fell	  between	  capsule	  sizes	  were	  rounded	  up	  to	  the	  nearest	  dose.	  	  	  	  
Dog	  Selection:	  	  	  	  	  	  	  	  	  	  	  	  	  	  Eligible	  subjects	  were	  client-­‐owned	  dogs	  who	  were	  admitted	  to	  the	  University	  of	  Minnesota	  Veterinary	  Medical	  Center	  (UMN	  VMC)	  between	  November	  2010	  and	  May	   2013	  with	   suspected	   IMHA.	   Informed	   consent	  was	   obtained	   from	   all	   owners	  before	   enrollment.	   The	   University	   Institutional	   Animal	   Care	   and	   Use	   Committee	  approved	   the	   study.	   	   All	   eligible	   subjects	   were	   evaluated	   and	   enrolled	   within	   24	  hours.	   A	   physical	   examination,	   complete	   blood	   count	   (CBC),	   serum	   biochemical	  profile,	   urinalysis,	   prothrombin	   time	   (PT),	   activated	   partial	   thromboplastin	   time	  (aPTT),	  D-­‐dimer,	  fibrinogen,	  antithrombin	  level	  (AT),	  4DX	  SNAP,	  arterial	  blood	  gas	  (ABG),	  and	  thoracic	  radiographs	  were	  performed	  on	  all	  patients	  within	  24	  hours	  of	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admission.	   A	   Coomb’s	   test	   was	   performed	   if	   there	   was	   no	   evidence	   of	   saline	  agglutination	  on	  the	  CBC.	  	  	  
Inclusion	  Criteria:	  	  Dogs	   were	   considered	   candidates	   for	   enrollment	   if	   there	   was	   a	   confirmed	  diagnosis	   of	   IMHA,	   characterized	   by	   regenerative	   anemia	   (hematocrit	   <30%	  with	  reticulocytes	   >60,000/uL)	   with	   evidence	   of	   hemolysis	   (hyperbilirubinemia,	  bilirubinuria,	   and/or	   hemoglobinuria)	   and	   one	   or	  more	   of	   the	   following:	   positive	  	  agglutination,	   spherocytosis,	   or	   a	   positive	   Coomb’s	   test.	   Slide	   agglutination	   was	  verified	  by	  the	  technical	  staff	  at	  the	  University	  of	  Minnesota	  Diagnostic	  lab	  by	  saline	  dispersion	   testing	   and	  microscopic	   review	   of	   the	   blood	   film.	   Coomb’s	   testing	  was	  performed	  using	  Standard	  Operating	  Procedures	  at	  the	  University	  of	  Minnesotaa.	  	  	  
Exclusion	  Criteria:	  	  Dogs	   with	   IMHA	   were	   excluded	   if	   there	   was	   any	   evidence	   that	   their	  hemolytic	   anemia	   was	   secondary	   to	   an	   identifiable	   cause	   based	   on	   thoracic	  radiographs,	   positive	   4DXb	   test	   (heartworm	   antigen,	   antibodies	   to	  Ehrlichia	   canis,	  
Anaplasma	  phagocytophilum,	  or	  Borrelia	  burgdorferi),	  or	  examination	  of	  blood	  film	  for	   erythroparasites	   or	   neoplastic	   cells,	   or	   history	   of	   exposure	   to	   drugs	   or	  compounds	  known	  to	  cause	  hemolysis.	  	  Dogs	   with	   body	  weight	   <5.0	   kg	   were	   excluded	   due	   to	   the	   need	   for	   repeat	  sampling	   for	   anti-­‐Xa	   levels.	   Dogs	   were	   also	   excluded	   if	   they	   had	   a	   platelet	   count	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<40,000/ul	   due	   to	   the	   need	   for	   jugular	   venipuncture,	   or	   PT	   or	   aPTT	   greater	   than	  twice	  the	  normal	  upper	  reference	  limit.	  	  Dogs	   were	   excluded	   if	   they	   received	   any	   treatment	   with	   any	  immunosuppressive	  medication	   for	   their	   anemia	   for	   greater	   than	   3	   days	   prior	   to	  enrollment	   or	   any	   immunosuppressive	   drug	   within	   the	   last	   six	   months,	   had	   any	  therapy	   with	   aspirin	   prior	   to	   enrollment,	   or	   were	   not	   enrolled	   and	   randomized	  within	  36	  hours	  after	  admission	  to	  the	  hospital.	  	  	  
Randomization:	  Dogs	  were	  randomized	  to	  either	  the	  IAD	  group	  or	  the	  LDA	  group	  the	  day	  of	  enrollment;	  dogs	  were	  randomized	  in	  groups	  of	  6	  using	  a	  table	  of	  random	  numbers	  and	  group	  assignments	  were	  placed	   in	  sequentially	  numbered	  sealed	  envelopes	  to	  be	   opened	   at	   the	   time	   of	   enrollment.	   Randomization	   and	   preparation	   of	   the	  envelopes	  was	  performed	  by	  an	  individual	  not	  directly	  involved	  in	  the	  study	  patient	  management.	   The	   primary	   clinician(s)	   involved	   in	   patient	   management	   were	  unaware	  of	  the	  study	  group	  designation	  for	  each	  dog.	  	  	  
Antithrombotic	  Therapy:	  	  Dogs	  in	  the	  IAD	  group	  were	  started	  on	  300IU/kg	  heparin	  SC	  every	  six	  hours	  for	  the	  first	  seven	  days,	  then	  every	  eight	  hours	  until	  day	  30,	  at	  which	  point	  the	  dose	  was	   reduced	   by	   15%	  each	   day	   for	   five	   days	   and	   discontinued.	   The	   heparin	   doses	  were	  adjusted	  based	  on	  the	  anti-­‐Factor	  Xa	  chromogenic	  assay	  checked	  on	  days	  3,	  4,	  5,	   7,	   14,	   21,	   and	  28	   to	  maintain	   the	  UH	   levels	  within	   the	   therapeutic	   range	   (0.35-­‐
 30 
 
0.7IU/ml).	  The	  adjustments	  were	  made	  by	  an	  unmasked	  investigator	  and	  relayed	  to	  the	   attending	   clinician.	   Dogs	   in	   this	   group	   also	   received	   an	   oral	   placebo	   capsule	  (calcium	  carbonate	  powder	  and	  yellow	  food	  coloring)	  that	  would	  be	  the	  equivalent	  of	  0.5	  mg/kg/day	  of	  5	  mg	  aspirin	  capsules.	  	  	   Dogs	   in	   the	   LDA	   group	  were	   started	   on	   aspirin	   at	   a	   dose	   of	   0.5	  mg/kg	   PO	  every	   24	   hours.	   5	   mg	   capsules	   were	   compounded	   for	   use	   (aspirin	   USP,	   calcium	  carbonate	   powder,	   and	   yellow	   food	   coloring).	   In	   cases	   where	   0.5	   mg/kg	   was	  between	  capsule	  doses,	  the	  number	  of	  capsules	  administered	  was	  rounded	  up	  to	  the	  next	  whole	  number.	  Aspirin	  was	  continued	  for	  30	  days,	  then	  discontinued.	  Dogs	  in	  the	   LDA	   group	   received	   injections	   of	   0.9%	   saline	   subcutaneously	   (SC)	   every	   six	  hours	  for	  seven	  days,	  then	  every	  8	  hours	  until	  day	  35,	  with	  a	  15%	  dose	  taper	  daily	  for	   the	   last	   5	   days.	   This	   was	   started	   assuming	   a	   concentration	   of	   10,000IU/ml	  heparin	  at	   a	  dose	  of	  300	  U/kg.	  The	  dose	  was	  adjusted	   randomly	  by	  an	  unmasked	  investigator	  and	  relayed	  to	  the	  attending	  clinician	  to	  maintain	  masking.	  	  
	  
Treatment	  and	  Monitoring	  Plan:	  Within	   the	   fist	   24	   hours	   after	   examination	   at	   the	   UMN	   VMC,	   dogs	   were	  managed	   with	   a	   standard	   treatment	   protocol	   in	   addition	   to	   their	   antithrombotic	  therapy.	   Therapy	   included	   immunosuppression,	   transfusions,	   crystalloid	   fluids,	  antibiotics,	   gastroprotectants,	   oxygen	   supplementation,	   and	   nutritional	   support	  according	  to	  this	  protocol.	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Immunosuppression	  was	  administered	  as	  dexamethasone	  SP	  at	  0.1	  mg/kg	  IV	  q12	  h	  if	  the	  dog	  was	  not	  tolerating	  oral	  medications.	  If	  the	  dog	  was	  tolerating	  oral	  medications,	  prednisone	  at	  1	  mg/kg	  PO	  q	  12	  hours,	  or	  30mg/m2/day	  (if	  the	  patient	  was	   >30kg)	  was	   administered.	   Prednisone	  was	   tapered	  when	   the	   hematocrit	  was	  within	   normal	   range	   (>36%)	   with	   no	   further	   evidence	   of	   hemolysis	   (lack	   of	  spherocytosis,	   reticulocytes	   <60,000/uL).	   Additional	   immunosuppressive	  medication	  was	  given	  at	  the	  clinician’s	  discretion.	  	  Packed	   red	   blood	   cell	   transfusions	  were	   administered	   in	   cases	  with	   a	   PCV	  <12%,	  acute	  decreases	  in	  PCV	  to	  <15%,	  tachycardia,	  or	  other	  clinical	  signs	  that	  were	  attributable	   to	   severe	   anemia.	   IV	   crystalloids	   were	   administered	   if	   clinically	  indicated	   to	  maintain	   hydration.	   Oxygen	   therapy,	   in	   the	   forms	   of	   nasal	   oxygen	   or	  oxygen	   cage,	   was	   provided	   if	   there	   were	   clinical	   signs	   of	   tachypnea,	   increased	  respiratory	  effort,	  or	  tachycardia	  were	  present,	  or	  at	  the	  discretion	  of	  the	  attending	  clinician.	   Antiemetics	   (ondansetronc,	   maropitantd,	   or	   metoclopramidee	   were	  administered	   in	  patients	  who	  were	  vomiting	  or	   inappetent,	  or	  at	   the	  discretion	  of	  the	  attending	  clinician.	  Gastric	  protection	  was	  administered	  at	  the	  discretion	  of	  the	  attending	  clinician.	  All	  patients	  were	  fed	  enterally	   if	  possible.	  A	  nasoesophageal	  or	  nasogastric	  tube	  was	  placed	  in	  cases	  of	  patients	  who	  were	  anorexic	  for	  >48	  hours.	  Antibiotic	  therapy	  was	  used	  if	  there	  was	  evidence	  of	  localizable	  infection.	  	  All	   samples	  aside	   from	  anti-­‐Factor	  Xa	   levels	  were	  drawn	   from	  a	  peripheral	  vein.	  PCV	  and	  vital	  signs	  (temperature,	  heart	  rate	  and	  pulse	  quality,	  respiratory	  rate	  and	   effort,	   mucous	   membrane	   color)	   were	   monitored	   every	   6-­‐12	   hours	   at	   the	  discretion	  of	  the	  attending	  clinician.	  Weight	  was	  monitored	  every	  6-­‐12	  hours.	  Urine	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production	   was	   estimated	   daily.	   Red	   blood	   cell	   morphology	   and	   the	   presence	   of	  autoagglutination	  was	  monitored	  daily	  during	  hospitalization.	  	  Packed	  cell	  volume	  (PCV)	  was	  monitored	  in	  all	  dogs	  and	  trough	  and	  peak	  (2	  hours	  post	  dose)	  heparin	  levels	  were	  monitored	  in	  IAD	  dogs	  on	  days	  3,	  4,	  and	  5.	  A	  CBC	  was	  monitored	  in	  all	  dogs	  and	  trough	  and	  peak	  heparin	  levels	  were	  monitored	  in	  IAD	  dogs	  on	  days	  7,	  14,	  21,	  and	  28.	  Heparin	   levels	  were	  assessed	  using	  an	  anti-­‐Factor	  Xa	  chromogenic	  assay59.	  Dogs	  in	  the	  LDA	  group	  had	  blood	  drawn	  to	  maintain	  blinding,	  but	  no	  anti-­‐Factor	  Xa	  test	  was	  run.	  Follow	  up	  examinations	  and	  a	  CBC	  were	  performed	  on	  days	  60,	  90,	  and	  180.	  	  
Anti-­Factor	  Xa	  Chromogenic	  Assay:	  Quantitative	  determination	  of	  unfractionated	  heparin	  was	  determined	  using	  a	   commercially	   available	   chromogenic	   assay	   kit	   for	   anti-­‐Factor	   Xa	   that	   has	   been	  validated	  for	  use	  in	  dogs59,	  g.	  The	  assays	  were	  performed	  using	  a	  FLOUstay	  OPTIMA	  microplate	  readerh.	  	  The	  blood	  samples	  were	  obtained	  via	  jugular	  venipuncture;	  2.7	  ml	  blood	  was	  collected	  into	  a	  3mL	  tube	  containing	  3.8%	  sodium	  citrate	  to	  result	  in	  a	  1:9	  ratio	  of	  citrate:whole	   blood.	   The	   sample	   was	   then	   centrifuged	   at	   2500	   x	   g	   at	   room	  temperature	  for	  ten	  minutes,	  and	  the	  plasma	  was	  harvested.	  1.2	  ml	  of	  plasma	  was	  diluted	  with	  0.4	  mL	  of	  Owren-­‐Kohler	  buffer59.	  The	  sample	  was	  then	  transported	  to	  the	  UMN	  Fairview	  Acute	  Care	  Laboratory	  and	  evaluated	  for	  anti-­‐Xa	  activity.	  	  
Additional	  Subjects:	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Due	   to	   the	   low	   enrollment	   in	   the	   prospective	   clinical	   trial,	   the	   treatment	  groups	  were	  augmented.	  	  Additional	   LDA	   dogs	   were	   identified	   by	   searching	   the	   electronic	   medical	  record	  for	  dogs	  with	  a	  diagnosis	  of	  primary	  IMHA	  that	  were	  seen	  at	  the	  UMN	  VMC	  between	   November	   2010	   and	   April	   2013.	   These	   dogs	   had	   to	   have	   a	   diagnosis	   of	  IMHA	   as	   for	   the	   dogs	   in	   the	   prospective	   clinical	   trial	   as	   well	   as	   meet	   inclusion	  criteria	  regarding	  diagnostic	  testing.	  These	  dogs	  also	  had	  to	  receive	  ultra	  low-­‐dose	  aspirin	  as	  part	  of	  their	  therapy	  for	  IMHA	  from	  the	  time	  of	  diagnosis.	  However,	  these	  dogs	  could	  be	  <5	  kg	  or	  could	  have	  been	  administered	  aspirin	  prior	  to	  admission.	  	  Additional	  IAD	  dogs	  were	  identified	  from	  a	  previous	  study	  performed	  at	  the	  UMN	  VMC48	  evaluating	  individually-­‐adjusted	  heparin	  therapy	  (versus	  standard	  dose	  therapy)	   in	   dogs	  with	   IMHA	   that	   had	   identical	   inclusion	   and	   exclusion	   criteria	   as	  well	  as	  the	  heparin	  dosing	  and	  monitoring	  protocol.	  	  
	  




Statistical	  Analysis:	  	  The	  IAD	  and	  the	  LDA	  dogs	  were	  evaluated	   for	  differences	  on	  enrollment	  or	  initial	  evaluation	  using	  a	  Wilcoxon	  signed-­‐rank	  test.	  The	  effect	  of	  group	  on	  survival	  and	   thromboembolic	   complications	   by	   day	   180	   was	   evaluated	   using	   a	   Fischer’s	  Exact	   Test.	   The	   association	   between	   laboratory	   abnormalities	   and	   survival	   or	  thromboembolism	   was	   evaluated	   using	   a	   Wilcoxon	   signed-­‐rank	   test.	   The	  associations	  between	  Antithrombin	  III	   levels	  and	   fibrin	  degradation	  products	  with	  thrombosis	   were	   evaluated	   with	   a	   Fisher’s	   Exact	   Test.	   Significance	   was	   set	   at	  P<0.05.	   Statistical	   analysis	   was	   performed	   using	   a	   standard	   statistical	   software	  packageg.	  	  	  
Results:	  	  Ten	   dogs	   were	   randomized	   to	   the	   IAD	   group.	   This	   group	   included	   7	  male	  neutered	  dogs	  and	  3	  female	  spayed	  dogs.	  The	  mean	  age	  of	  this	  group	  was	  6.4	  years	  (range,	   3-­‐10	   years).	   Breeds	   represented	   included	   1	   each	   of	   the	   following:	   Welsh	  Terrier,	  Shih	  Tzu,	  American	  Staffordshire	  Terrier,	  English	  Springer	  Spaniel,	  Cocker	  Spaniel,	  English	  Setter,	  Lhasa	  Apso,	  Viszla,	  Labrador	  Retriever,	  and	  Dachshund.	  	  Twelve	   dogs	   were	   randomized	   to	   the	   LDA	   group.	   Included	   were	   6	   male	  neutered	  dogs	  and	  6	  female	  spayed,	  with	  a	  mean	  age	  of	  6.5	  years	  (range,	  1-­‐9	  years).	  Breeds	   included	   American	   Staffordshire	   Terrier	   (3),	   English	   Springer	   Spaniel	   (2),	  and	  one	  each	  of	  the	  following:	  Pembroke	  Welsh	  Corgi,	  Toy	  Poodle,	  Boston	  Terrier,	  German	  Shepherd	  Dog,	  Labradoodle,	  and	  Australian	  Cattle	  Dog.	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Eight	   dogs	   who	   received	   individually-­‐adjusted	   heparin	   therapy	   were	  extracted	   from	   a	   previous	   study17.	   This	   group	   included	   7	   neutered	   males	   and	   1	  spayed	  female.	  The	  mean	  age	  of	  this	  group	  was	  7.75	  years	  (range,	  1-­‐13	  years).	  	  The	  following	  breeds	  were	  represented	  in	  this	  group:	  Shih	  Tzu	  (2)	  and	  1	  each	  of	  the	  following:	  Standard	  Poodle,	  Fox	  Terrier,	  Cavalier	  King	  Charles	  Spaniel,	  Collie,	  Dachshund,	  and	  Airedale.	  	  Ten	  additional	  dogs	  with	  IMHA	  who	  received	  aspirin	  therapy	  were	  identified.	  This	  group	  included	  2	  neutered	  males	  and	  8	  spayed	  females.	  Mean	  age	  of	  this	  group	  was	  6.6	  years	  (range,	  1-­‐13	  years).	  	  Breeds	  included	  in	  this	  group	  were	  Shih	  Tzu	  (2),	  Miniature	  Schnauzer	  (2),	  and	  one	  each	  of	  Brittany	  Spaniel,	  Shetland	  Sheepdog,	  Collie,	  Boston	  Terrier,	  Pekingese,	  and	  German	  Shepherd	  Dog.	  	  With	   the	   treatment	  groups	   together,	   there	  were	  18	  dogs	  who	   received	   IAD	  therapy.	  Overall,	   this	   group	   included	  14	  male	  neutered	  dogs	   and	  4	   spayed	   female	  dogs,	  with	  a	  mean	  age	  of	  6.4	  years.	  	  There	  were	  22	  dogs	  who	  received	  ultra	  low-­‐dose	  aspirin.	  This	  group	  included	  8	  neutered	  males	  and	  14	  spayed	  females;	  the	  mean	  age	  of	  this	  group	  was	  5.7	  years.	  	  There	   was	   no	   significant	   difference	   in	   the	   age	   of	   the	   dogs	   between	   the	  groups.	  The	  male	  dogs	  were	  overrepresented	  in	  the	  IAD	  group,	  and	  the	  female	  dogs	  in	  the	  LDA	  group.	  There	  was	  no	  difference	  between	  the	  groups	  as	  far	  as	  BUN,	  total	  serum	  bilirubin,	   PT	   and	   aPTT,	   or	   band	  neutrophil	   counts	   at	   the	   time	   of	   diagnosis	  (table	  1).	  The	  average	  total	  bilirubin	  values	   for	  the	  groups	  were	  6.1mg/dl	   for	  LDA	  and	  1.4	  mg/dl	  for	  aspirin,	  but	  this	  difference	  was	  not	  statistically	  significant	  (p=0.1).	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Four	  of	  the	  18	  dogs	  who	  received	  LDA	  had	  a	  total	  serum	  bilirubin	  over	  5	  mg/dl.	  Two	  dogs	  were	  euthanized	  the	  day	  after	  diagnosis	  due	  to	  severe	  ongoing	  hemolysis;	  one	  had	  a	  bilirubin	  of	  53.3	  mg/dl	  and	  one	  had	  a	  value	  of	  6.9	  mg/dl.	  Two	  dogs	  survived	  past	  180	  days;	  one	  dog	  had	  a	  bilirubin	  of	  20.6	  mg/dl	  and	  one	  had	  a	  value	  of	  12.9	  mg/dl.	  	  	  
Survival:	  	  Thirteen	   of	   the	   22	   dogs	   in	   the	   LDA	   group	   survived	   to	   the	   endpoint	   of	   180	  days.	  	  Of	  the	  9	  dogs	  that	  did	  not	  survive,	  7	  died	  or	  were	  euthanized	  within	  1	  week	  of	  diagnosis;	  one	  dog	  was	  euthanized	  at	  day	  10,	  and	  one	  at	  day	  27.	  	  Thirteen	  of	  the	  18	  dogs	  in	  the	  IAD	  group	  survived	  to	  180	  days.	  Of	  the	  5	  dogs	  who	  did	  not	   survive,	   4	   died	   within	   one	   week	   of	   diagnosis.	   One	   dog	   died	   at	   9	   days	   post-­‐diagnosis.	  	  There	  was	  no	  difference	   in	   the	  proportion	  of	  dogs	  between	  the	  groups	  that	  did	  not	  survive	  (p=0.18).	  	  There	  was	  no	  difference	  in	  the	  age	  of	  the	  dogs	  between	  groups	  who	  survived.	  There	  was	  no	  difference	  in	  the	  BUN	  (p=0.2),	  ALP	  (p=0.6),	  PT	  (0.44),	  aPTT	  (0.4),	  or	  band	  neutrophil	  count	  (0.25).	  The	  difference	  in	  total	  bilirubin	  between	  the	  dogs	  who	  survived	   and	   those	   who	   did	   not	   was	   approaching	   significance,	   but	   was	   not	  significant	   at	   a	   p	   of	   0.09.	   There	  was	   no	  difference	   in	   antithrombin	   level	   (p=0.19),	  FDPs	   (p=0.86),	   or	   fibrinogen	   (p=0.13)	   between	   the	   dogs	  who	   survived	   and	   those	  who	  did	  not.	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Thrombosis	  and	  Causes	  of	  Death:	  	  Eight	   of	   the	   22	   dogs	   in	   the	   LDA	   group	   had	   possible	   or	   confirmed	  thromboembolic	   complications.	   Two	   dogs	   had	   suspected	   pulmonary	  thromboemboli	   (PTE),	  based	  on	  acute	  dyspnea	  and	  hypoxemia.	  One	  of	   these	  dogs	  survived	  to	  study	  completion	  and	  one	  was	  euthanized	  due	  to	  the	  thrombus	  as	  well	  as	   refractory	   hemolysis.	   One	   dog	   had	   arterial	   thrombosis	   to	   3	   feet,	   and	   one	   had	  venous	   thrombosis	   to	   a	   foreleg.	   Both	   of	   these	   dogs	   were	   euthanized	   due	   to	  complications	   from	   these	   thromboses.	   Two	   dogs	   had	   PTE	   concurrent	   with	   other	  organ	  thrombi	  (spleen	  and	  liver	  in	  one,	  adrenal	  in	  the	  second),	  which	  were	  found	  on	  post-­‐mortem	   examination.	   These	   dogs	   were	   euthanized	   due	   to	   dyspnea	   and	  deteriorating	   clinical	   condition.	   One	   dog	   was	   euthanized	   due	   to	   poor	   clinical	  condition,	  and	  had	  hepatic	  venous	  and	  sinusoidal	  thrombosis	  found	  on	  post-­‐mortem	  examination.	  One	  dog	  developed	  a	  thrombus	  in	  the	  caudal	  vena	  cava;	  this	  thrombus	  was	  identified	  on	  ultrasound	  after	  ascites	  was	  noted	  on	  physical	  examination.	  This	  dog	  had	  eventual	   resolution	  of	  her	   thrombus	  and	   survived	   to	   completion.	  Overall,	  two	  dogs	  who	  experienced	  thromboembolic	  complications	  survived	  to	  180	  days.	  	  	  Other	  causes	  of	  death	  in	  the	  LDA	  group	  included	  one	  case	  of	  pyelonephritis	  leading	   to	   renal	   failure,	   and	   two	  dogs	  who	  had	   continued	  hemolysis	   that	  was	   not	  responsive	  to	  immunosuppressive	  therapy.	  	  Two	   of	   the	   18	   dogs	   in	   the	   IAD	   group	   had	   possible	   or	   confirmed	  thromboembolic	   complications.	  One	  dog	  developed	  acute	  dyspnea	  and	  hypoxemia	  and	  had	  a	  suspected	  PTE;	  the	  second	  developed	  a	  suspected	  PTE	  and	  had	  a	  portal	  
 38 
 
thrombus	  noted	  on	  post-­‐mortem	  examination.	  Both	  of	  these	  dogs	  were	  euthanized	  within	  24	  hours	  of	  onset	  of	  clinical	  signs.	  	  Three	  additional	  dogs	  in	  the	  IAD	  group	  did	  not	  survive;	  one	  dog	  experienced	  hematemesis	  and	  deteriorating	  clinical	  condition,	  one	  was	  refractory	  to	  therapy	  and	  had	  a	  decline	  in	  clinical	  condition,	  and	  one	  dog	  developed	  non-­‐regenerative	  anemia.	  	  There	   was	   no	   statistical	   difference	   in	   the	   number	   of	   dogs	   with	  thromboembolic	  complications	  between	  the	  two	  groups	  of	  dogs,	  but	  it	  did	  approach	  significance	  (p=0.07)	  (Table	  2).	  	  	  
Hemorrhagic	  Complications:	  Two	   dogs	   in	   the	   AID	   group	   had	   non-­‐fatal	   hemorrhagic	   complications.	   	   No	  dogs	   in	   the	   LDA	   group	   had	   hemorrhagic	   complications.	   There	   was	   no	   significant	  difference	  in	  the	  number	  of	  dogs	  who	  had	  hemorrhagic	  complications	  between	  the	  groups	  (p=0.2).	  	  	  
Hospitalization	  and	  Therapy:	  	  The	  median	   length	   of	   hospitalization	   for	   the	   dogs	   in	   the	   IAD	   group	  was	   3	  days	  (range,	  0-­‐9	  days)	  and	  4	  days	  (range,	  0-­‐9	  days)	  for	  the	  dogs	  in	  the	  LDA	  group.	  In	  the	  IAD	  group,	  4	  dogs	  received	  no	  packed	  red	  blood	  cell	  transfusion,	  8	  dogs	  received	  one,	  5	  dogs	  received	  2,	  and	  one	  dog	  received	  3.	  In	  the	  LDA	  group,	  4	  dogs	  received	  no	  packed	  red	  blood	  cell	  transfusions,	  4	  dogs	  received	  one,	  9	  dogs	  received	  two,	  3	  dogs	  received	  3,	  and	  1	  dog	  received	  4.	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No	   dog	   had	   been	   treated	   with	   any	   immunosuppressive	   or	   anticoagulant	  therapy	  prior	  to	  admission.	  All	  dogs	  received	  prednisone.	  	  In	   the	   IAD	   group,	   concurrent	   immunosuppressive	   therapies	   included	  azathioprine	  in	  14	  dogs,	  cyclosporine	  in	  3	  dogs,	  and	  mycophenolate	  in	  1	  dog.	  In	  the	  LDA	  group,	  9	  dogs	  received	  azathioprine	  and	  5	  received	  mycophenolate	  in	  addition	  to	  prednisone.	  	  
	  




	   The	  results	  of	  this	  study	  are	  encouraging	  for	  the	  use	  of	  individually-­‐adjusted	  heparin	   therapy	   for	   thrombophylaxis	   in	   dogs	   with	   IMHA.	   Critical	   to	   note	   in	   this	  study	   is	   that	   it	   was	   underpowered;	   power	   analysis	   prior	   to	   enrollment	  demonstrated	  that	  to	  achieve	  80%	  power,	  30	  dogs	  in	  each	  group	  would	  need	  to	  be	  enrolled.	   22	   dogs	   were	   enrolled	   in	   the	   blinded,	   placebo-­‐controlled	   study,	   and	   18	  other	  dogs	  were	  identified	  as	  cohorts	  to	  add	  statistical	  power,	  although	  appropriate	  power	  (80%)	  was	  still	  not	  met	  by	  a	  deficit	  of	  20	  dogs.	  The	  slow	  enrollment	  was	  the	  largest	  challenge	  encountered	  in	  this	  study.	  Given	  that	  the	  study	  was	  underpowered	  and	  therefore	  at	  risk	  for	  Type	  II	  error,	  the	  near	  significant	  difference	  in	  thrombotic	  complications	  between	   the	   two	  groups	  of	  dogs	   is	  very	  compelling,	   implying	   that	  a	  true	  difference	  may	  be	  present,	  and	  strongly	  warrants	  further	  investigation	  into	  the	  possible	  benefits	  of	  IAD	  therapy	  for	  prevention	  of	  thrombosis.	  The	  results	  obtained	  lend	   confidence	   to	   continuation	  of	   study	  and	  possibility	   that	   individually	   adjusted	  heparin	  could	  improve	  outcome.	  	  This	   study	   corroborated	   previous	   studies	   evaluating	   risk	   factors	   for	  thrombosis	  in	  dogs	  with	  IMHA.	  It	  has	  been	  documented	  that	  elevations	  in	  BUN,	  total	  bilirubin,	   and	   increased	   aPTT	   are	   associated	   with	   an	   increased	   risk	   for	  thromboembolic	   complications2,	   19.	   As	   has	   also	   been	   reported,	   the	  majority	   of	   the	  thromboses	  occurred	  within	  the	  first	  few	  weeks	  of	  therapy11,	  20.	  Similar	  to	  previous	  findings21,	  there	  was	  no	  association	  between	  AT	  III	  and	  increased	  risk	  of	  thrombosis	  although	  many	  of	   the	  dogs	   in	  our	  study	  had	  antithrombin	   III	   levels	   that	  measured	  below	  normal.	  Previous	  studies2,	  15	  have	  also	  found	  an	  increased	  risk	  of	  thrombosis	  with	  elevated	  band	  neutrophil	  counts,	  which	  was	  not	  found	  in	  the	  current	  study.	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Interestingly,	   there	  was	  no	  difference	   in	   the	  mortality	   between	   the	   two	   groups	  of	  dogs,	  nor	  was	  there	  an	  association	  between	  any	  of	  the	  clinicopathologic	  findings	  and	  mortality,	   although	   again,	   Type	   II	   error	   may	   account	   for	   that.	   Many	   of	   the	  thromboses	  that	  were	  encountered	  by	  the	  dogs	  were	  non-­‐fatal	  and	  were	  survived.	  Another	   reason	   for	   the	   lack	   of	   difference	   in	   survival	   between	   groups,	   while	   a	  difference	   in	   thrombosis	   is	   suggested,	   is	   that	   some	   dogs	   did	   not	   die	   from	   their	  thromboses.	   Those	   dogs	   tended	   to	   succumb	   to	   their	   disease	   due	   to	   persistent	  hemolysis,	   often	   resulting	   in	   overwhelming	   transfusion	   demands.	   This	   places	   a	  significant	   financial	   demand	   on	   the	   client,	   and	   is	   often	   a	   cause	   for	   electing	  euthanasia.	   It	  would	  be	   interesting	   to	  evaluate	  whether	   survival	  would	  have	  been	  different	  if	  finances	  had	  not	  been	  a	  factor.	  Returning	  to	  the	  data	  and	  censoring	  the	  dogs	  who	  did	  not	  die	  of	  thrombosis,	  and	  repeating	  the	  analysis	  on	  the	  relationship	  between	  treatment	  group	  and	  survival	  is	  the	  next	  step	  to	  take.	  	  Thromboses	  were	   found	  to	  be	  both	  venous	  and	  arterial	   in	  our	  study.	  Other	  causes	   of	   death	  were	   due	   to	   the	   refractory	   nature	   of	   some	   of	   the	   cases;	   repeated	  transfusions	   are	   often	   financially	   limiting	   for	  many	   clients,	   and	   in	   some	   cases	   the	  IMHA	  caused	  sufficient	  morbidity	  to	  impact	  quality	  of	  life	  significantly.	  	  It	   is	   possible	   that	   there	   were	   more	   thrombotic	   complications,	   possibly	   in	  both	   groups	   of	   dogs,	   than	   were	   accounted	   for.	   This	   may	   be	   a	   source	   of	  misclassification	   that	   could	   also	   contribute	   to	   the	   lack	  of	   statistical	   significance	   in	  the	   present	   study.	   Not	   all	   dogs	   had	   post-­‐mortem	   examinations,	   and	   clot	   lysis	   is	  reported	  to	  occur	  quickly	  post-­‐mortem,	  so	  it	  is	  possible	  that	  there	  were	  thromboses	  that	  were	  missed	  in	  dogs	  who	  did	  have	  a	  post-­‐mortem	  examination.	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With	   the	   small	   number	   of	   dogs	   in	   this	   study,	  we	  were	   unable	   to	   correlate	  additional	  therapies,	  such	  as	  the	  use	  of	  secondary	  immunosuppressives,	  antibiotics,	  or	  anti-­‐nausea	  medications	  with	  mortality.	  The	  study	  size	  was	  the	  largest	  challenge	  encountered	  in	  this	  trial.	  The	  exclusion	  criteria	  were	  the	  largest	  reason	  for	  this,	  as	  many	  dogs	  were	  admitted	   that	  had	   received	  aspirin	   therapy	  already.	  Additionally,	  more	   active	   recruitment	   from	   the	   surrounding	   primary	   care	   hospitals	   could	   have	  been	  pursued.	  	  In	   addition	   to	   pursuing	  more	   cases	   to	   continue	   this	   study,	   there	   are	   other	  questions	   that	   would	   be	   interesting	   to	   pursue.	   The	   anti-­‐Xa	   target	   range	   is	  specifically	  for	  humans,	  although	  the	  test	  has	  been	  validated	  in	  dogs.	  Because	  dogs	  with	  IMHA	  often	  have	  low	  ATIII	  levels,	  it	  would	  be	  interesting	  to	  evaluate	  whether	  dogs	   with	   IMHA	   have	   a	   different	   anti-­‐Xa	   target	   range.	   The	   relationship	   between	  anti-­‐Xa	   and	   low	   ATIII	   has	   not	   been	   evaluated	   in	   dogs,	   and	   given	   that	   ATIII	   is	  necessary	   for	   unfractionated	   heparin	   to	   work,	   it	   may	   be	   important	   to	   determine	  whether	   the	   range	   for	   these	  dogs	  differs	   from	   the	  normal	  population	   if	   it	   is	   to	  be	  used	  for	  heparin	  adjustment.	  	  	  	   Another	   interesting	   issue	   that	   arose	   when	   performing	   this	   study	   was	  inadvertent	   unmasking	   of	   the	   attending	   clinicians.	   There	   were	   communication	  errors	  that	  included	  the	  dog	  group	  assignment,	  or	  poor	  placement	  of	  the	  assignment	  list	  by	  staff.	  As	  the	  outcome	  measure	  was	  fairly	  objective,	  however,	  it	  is	  unlikely	  that	  occasional	  unmasking	  affected	  the	  endpoint	  assessment.	  	  	   One	   issue	   that	   also	   came	   up	   when	   performing	   this	   study	   was	   the	   owner	  stress	   regarding	   the	   enrollment	   of	   their	   dog	  when	   they	   have	   just	   been	   diagnosed	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with	   a	   new,	   potentially	   fatal,	   and	   likely	   expensive,	   disease.	   Some	   owners	   were	  excited	   to	   participate,	   and	   perhaps	   felt	   a	   sense	   of	   control,	   whereas	   others	   felt	  overwhelmed.	   It	   was	   impossible	   to	   predict	   the	   reactions	   owners	   would	   have,	   so	  both	  had	  to	  be	  anticipated	  and	  treated	  with	  equal	  respect.	  	  In	   conclusion,	   this	   study	   provides	   support	   for	   the	   continued	   evaluation	   of	  individually	  adjusted	  heparin	  therapy	   for	   the	  use	  of	   thrombophylaxis	   in	  dogs	  with	  IMHA.	   There	   is	   a	   strong	   trend	   towards	   a	   significant	   decrease	   in	   thromboembolic	  complications	  in	  dogs	  who	  received	  individually	  adjusted	  heparin	  relative	  to	  those	  on	  ultra	  low-­‐dose	  aspirin.	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Chapter	  3:	  Safety of ultrasound-guided fine-needle aspiration of the feline pancreas: 
A case-control study 	  
Abstract:  
The safety of fine-needle aspiration (FNA) of the feline pancreas has not been reported. 
The incidence of complications following ultrasound-guided pancreatic FNA in 73 cats 
(PA cats) with clinical and sonographic evidence of pancreatic disease was compared to 
complications in two groups of matched control cats also diagnosed with pancreatic 
disease who either had abdominal organs aspirated other than the pancreas (Control-
FNA, n=63) or no aspirates performed (Control-No FNA, n=61). The complication rate 
within 48 hours of the aspirate procedure did not differ among the PA cats (11%), 
Control-FNA (14%), or Control-No FNA (8%) cats. There was no difference in rate of 
survival to discharge  (82%, 84%, and 83%, respectively) or length of hospital stay 
among groups. The cytologic recovery rate for the pancreatic samples was 67%. 
Correlation with histopathology, available in 7 cases, was 86%. Pancreatic FNA in cats is 




 The clinical importance of feline pancreatic disease is increasingly being 
recognized. A pathologic classification has been proposed, including various 
histopathological types of pancreatitis, nodular hyperplasia, neoplasia, pancreatic 
pseudocyst, abscess, amyloid deposition, and pancreatic atrophy60.   In addition to the 
broad spectrum of diseases, the clinical picture is further complicated by the potential for 
pancreatic disease to present concurrently with inflammatory bowel disease and/or 
cholangitis61.  Given the significance of pancreatic diseases in cats, there is a pressing 
need for minimally-invasive diagnostic tests to distinguish among inflammatory, 
hyperplastic, and neoplastic lesions.  
 Ultrasound is often used in conjunction with clinical and laboratory findings to 
identify pancreatic disease. Abdominal ultrasonography is safe and has good specificity 
for the presence of pancreatitis, but has suboptimal sensitivity, reportedly 30-80% in 
cats62,  63, 64. Additionally, ultrasonography cannot reliably differentiate among different 
pathologic processes in the pancreas 64, 65, 66. Nodular pancreatic change raises concern for 
neoplasia, but is not specific65, and may also occur with inflammatory disease67. 
 Obtaining samples of abdominal organs by ultrasound-guided fine-needle 
aspiration (FNA) for cytologic evaluation is a reasonably safe and accurate diagnostic 
modality that often augments imaging studies. In human medicine, pancreatic FNA has a 
complication rate of 1.5%68 -3%68, 69, 70. Diagnostic performance is good, with reported 
sensitivity of 92.5%71 and specificity of 68%72- 100%68 for neoplasia. Few studies have 
addressed pancreatic FNA in cats64. 65. 72. Although no complications have been reported in 
the 17 cats evaluated in these studies, speculation about potential risks following 
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pancreatic sampling may contribute to reluctance to perform pancreatic FNA. Currently, 
there seems to be a tendency among some clinicians to shy away from performing feline 
pancreatic FNA. It is a commonly-held belief that aspirating an inflamed pancreas will 
contribute to the inflammatory state and result in more severe pancreatitis. Although this 
is reported as a rare side effect in humans, it has not been described in the veterinary 
literature, and no safety data for this procedure exists. 	  
 The primary objective of this study was to evaluate the safety of FNA of the 
feline pancreas with clinical and ultrasonographic evidence of pancreatic disease. 
Secondary objectives were to evaluate the diagnostic yield of samples obtained by 
ultrasound-guided pancreatic FNA and the type of diagnostic information obtained. We 
hypothesized that FNA of the feline pancreas would be safe, providing diagnostically 
useful information in the majority of cases.  	  
Materials	  and	  methods:	  
Case	  selection	  and	  matching	  with	  controls:	  	   The	   electronic	   medical	   record	   system	   at	   the	   University	   of	   Minnesota	  Veterinary	   Medical	   Center	   was	   searched	   for	   cats	   having	   pancreatic	   cytology	  performed	   from	   September	   2004	   through	   September	   2011.	   	   Inclusion	   criteria	   for	  pancreatic	  aspirate	  (PA)	  cats	  consisted	  of	  1)	  abdominal	  ultrasound	  performed	  by	  a	  board	   certified	   veterinary	   radiologist	   in	   cats	   with	   clinicopathologic	   changes	  compatible	   with	   pancreatic	   disease,	   2)	   ultrasonographically-­‐identified	   pancreatic	  lesions,	  3)	  FNA	  of	  the	  pancreas	  performed	  with	  ultrasound	  guidance,	  4)	  successful	  pancreatic	   aspirate	   confirmed	   during	   imaging	   or	   by	   cytologic	   evaluation	   and	   5)	   a	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complete	   medical	   record	   with	   hospitalization	   for	   a	   minimum	   of	   48-­‐hours	   post-­‐ultrasound	  +/-­‐	  aspirate	  procedure.	  	  Cases	  were	  excluded	  if	  the	  required	  information	  was	  not	  available.	  	  	  	   	  The	   population	   from	   which	   control	   cats	   were	   matched	   to	   PA	   cats	   was	  identified	   by	   searching	   the	   ultrasound	   log	   from	   September	   2004	   to	   September	  2011	   for	   consecutive	   feline	   cases	   having	   ultrasonographic	   abnormalities	   of	   the	  pancreas	  or	  peripancreatic	   tissue,	  with	  no	  pancreatic	  FNA	  performed.	   Inclusion	  criteria	  1,	  2	  and	  5	  were	  otherwise	  identical	  to	  PA	  cats.	  Two	  controls	  groups	  were	  formed:	   control	   FNA	   cats	   had	   ultrasound-­‐guided	   FNA	   or	   biopsies	   of	   abdominal	  organs	   other	   than	   the	   pancreas	   and	   control-­‐No	   FNA	   cats	   did	   not	   have	   any	  sampling	  of	   intra-­‐abdominal	  organs	  or	   tissues	  performed	  during	  the	  ultrasound	  procedure.	  We	  attempted	   to	  match	  PA	   cats	   to	  one	   control	   from	  each	  group.	  PA	  cats	   and	   controls	  were	   first	  matched	   based	   on	   age	   group	   (0-­‐8	   years,	   9-­‐15,	   and	  >16	  years	  of	  age)	  and	  date	  of	  ultrasound	  (within	  6	  months	  of	   the	  PA	  case).	   	  To	  attempt	  to	  control	  for	  illness	  severity,	  controls	  were	  then	  matched	  with	  PA	  cases	  based	  on	   location	  of	  hospitalization	  (Intensive	  Care	  Unit	  or	  general	  wards)	  and,	  finally,	   on	   type	  and	   severity	  of	  pancreatic	   and	  peripancreatic	   tissue	   changes	  on	  ultrasound.	   Cases	   and	   controls	   were	   matched	   first	   on	   pancreatic	   size,	  echotexture,	   and	  margin	   irregularity,	   then	  on	  presence	   of	  masses,	   nodules,	   and	  peritoneal	  effusion.	  Ultrasound	  reports	  for	  cats	  in	  all	  groups	  were	  evaluated	  and	  the	   following	   information	   about	   the	   pancreas	   was	   recorded:	   pancreatic	   size,	  margin	   irregularity,	   echotexture,	   and	   the	   presence	   or	   absence	   of	   masses	   or	  nodular	   lesions	   (size,	   shape,	   number).	   Peripancreatic	   changes,	   including	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mesenteric	   echogenicity	   changes,	   peritoneal	   effusion,	   and	   hepatic	   echotexture	  abnormalities	  were	  also	  recorded.	  	  	  
Data	  collection:	  	   Signalment,	   historical	   illnesses,	   serum	   liver	   enzyme	   activities,	   serum	  bilirubin,	  and	  creatinine	  concentrations	  prior	  to	   imaging	  were	  recorded	  for	  cats	   in	  all	   groups.	   Length	   of	   hospital	   stay,	   discharge	   status	   (alive,	   died,	   or	  euthanized/discharged	   to	   be	   euthanized	   within	   24	   hours),	   clinical	   diagnosis,	   and	  concurrent	  diagnoses	  based	  on	  record	  review	  were	  noted.	  	  Records	  were	  evaluated	  to	  determine	  if	  any	  of	  the	  following,	  designated	  as	  “complications”,	  occurred	  within	  48	   hours	   after	   the	   abdominal	   ultrasound:	   hemoabdomen,	   hypotension,	   need	   for	  corrective	   clinical	   action	   (transfusion,	   diagnostic	   abdominocentesis	   or	   peritoneal	  lavage),	  or	  respiratory	  distress.	  It	  was	  also	  recorded	  if	  suspicion	  of	  any	  of	  the	  above	  complications	  lead	  to	  recheck	  abdominal	  ultrasound	  within	  48	  hours	  of	  the	  original	  procedure.	  	  	  
Pancreatic	  FNA	  procedure	  and	  cytologic	  classification:	  Aspirates	  were	  obtained	  with	  a	  20	  or	  22	  gauge	  hypodermic	  or	  spinal	  needle	  of	   an	   adequate	   length	   to	   reach	   the	  pancreas	  or	   other	   organ	  or	   tissue	  using	   either	  aspiration	   or	   fenestration	   techniques,	   or	   a	   combination	   of	   both67.	   This	   is	   the	  procedure	  typically	  used	  for	  intra-­‐abdominal	  aspirates	  of	  solid	  tissues.	  Multiple	  FNA	  attempts,	  usually	  2-­‐3,	  are	  standardly	  made	  for	  tissue	  sampling	  in	  our	  hospital;	  one	  attempt	  is	  typically	  performed	  for	  fluid.	  Pancreatic	  cytology	  reports	  generated	  by	  a	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board-­‐certified	  veterinary	  clinical	  pathologist	  were	  reviewed	  and	  the cellularity	  of	  the	  cytologic	  samples	  and	  cytologic	  diagnosis(es)	  for	  the	  pancreas	  noted.	  Cytologic	  recovery	  rate	  was	  defined	  as	   the	  percent	  of	  samples	   from	  the	  total	  submitted	  that	  were	   diagnostic.	   Cytologic	   diagnoses	   were	   categorized	   as	   normal	   exocrine	   tissue,	  cyst,	   necrosis/inflammation,	   hyperplasia,	   neoplasia,	   or	   nondiagnostic.	   For	   a	  diagnosis	   of	   neoplasia,	   the	   cell	   of	   origin	   or	   specific	   tumor	   type	   was	   recorded,	   if	  determined.	   Histopathologic	   diagnosis	   from	   surgical	   or	   necropsy	   samples	   were	  recorded	   when	   available,	   and	   the	   interval	   between	   cytologic	   and	   histopathologic	  evaluation	  recorded.	  	  	  
Statistical	  analysis:	  The	   chi-­‐squared	   test	   of	   association	   was	   used	   to	   assess	   differences	   among	  groups	  in	  sex,	  frequency	  of	  complications,	  location	  of	  hospitalization,	  and	  discharge	  status.	   Cats	   that	   died	   or	   were	   discharged	   to	   be	   euthanized	   were	   combined	   for	  analysis.	   Factors	   used	   for	   matching	   cases	   to	   controls	   were	   not	   evaluated	   for	  differences,	   except	   for	   ultrasonographic	   features	   of	   the	   pancreas,	   as	  matching	   for	  these	  criteria	  was	  incomplete.	  The	  data	  were	  tested	  for	  normality,	  and	  ANOVA	  was	  used	   to	   evaluate	   differences	   among	   the	   groups	   in	   pre-­‐ultrasound	   serum	   liver	  enzyme	   activities,	   bilirubin,	   creatinine,	   and	   frequency	   of	   concurrent	   diseases.	  Differences	   in	   length	   of	   hospital	   stay	  were	   evaluated	   using	   a	   linear	  mixed	  model	  with	   group	   (PA,	   control-­‐FNA,	   or	   control-­‐No	   FNA),	   location	   of	   hospitalization,	   age	  group,	  and	  discharge	  status	  as	  fixed	  effects	  and	  the	  matched	  cats	  as	  a	  random	  effect.	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The	  most	  common	  distributions	  of	  clinical	  pathologic	  category	  of	  pancreatic	  disease	  for	  PA	  cats	  were	  described.	  Values	  of	  p<0.05	  were	  considered	  significant.	  	  
Results:	  
Study	  population:	  	  	   Ninety-­‐five	   possible	   PA	   cats	   were	   identified;	   22	   were	   excluded	   due	   to	  inability	  to	  confirm	  pancreatic	  aspiration.	  Of	  73	  remaining	  PA	  cats,	  51	  were	  matched	  to	  two	  controls	  (21	  with	  both	  controls	  from	  the	  same	  control	  group	  and	  nine	  with	  one	  from	  each	  control	  group).	  Twenty-­‐two	  PA	  cats	  had	  a	  single	  control.	  Of	  the	  162	  cats	   identified	   as	   potential	   controls,	   38	   were	   excluded	   for	   inability	   to	   be	  satisfactorily	  matched	  to	  a	  PA	  cat.	  	  	   Overall,	   197	   cats	   were	   included	   in	   this	   study,	   of	   which	   77	   were	   spayed	  females	  and	  120	  were	  neutered	  males.	  The	  mean	  age	  was	  12.2	  years	  (range	  3-­‐19).	  The	  PA	  group	  (n=73)	  consisted	  of	  28	  spayed	   females	  and	  45	  neutered	  males	  with	  mean	   age	   of	   13.4	   years	   (range	   3-­‐18).	   Of	   63	   Control-­‐FNA	   cats,	   20	   were	   spayed	  females	  and	  43	  were	  neutered	  males.	  The	  mean	  age	  was	  12.0	  years	  (range	  6-­‐18).	  	  Of	  61	  Control-­‐No	  FNA	  cats,	  29	  were	  spayed	  females	  and	  32	  were	  neutered	  males.	  The	  mean	  age	  was	  11.1	  years	  (range	  3-­‐19).	  Sex	  distribution	  did	  not	  differ	  among	  groups	  (p=0.24)	  (Table	  3).	  	  	  
Hospitalization:	  	   The	   means	   for	   lengths	   of	   hospital	   stay	   were:	   	   PA	   2.77	   days	   (range	   1-­‐7),	  Control-­‐FNA	  2.49	  days	  (range	  1-­‐11)	  and	  Control-­‐No	  FNA	  3.0	  days	  (range	  1-­‐9),	  with	  
 51 
 
no	   significant	   differences	   among	   the	   three	   groups	   (p=0.7).	   Control-­‐No	   FNA	   cats	  were	   3	   times	   as	   likely	   to	   be	   hospitalized	   in	   the	   general	   wards	   than	   the	   ICU	  (p<0.001),	  while	  the	  other	  groups	  were	  more	  evenly	  distributed	  between	  locations	  (Table	  3).	  	  	  
Biochemical	  analyses:	  	  	   There	   were	   no	   significant	   differences	   in	   serum	   activities	   of	   ALT	   (p=0.17),	  ALP	  (p=0.68),	  GGT	  (p=0.69),	  or	  serum	  creatinine	  concentration	  (p=0.15)	  (Table	  3).	  The	   Control-­‐FNA	   group	   had	   a	   higher	  mean	   bilirubin	   than	   the	   PA	   and	   Control-­‐No	  FNA	  cats	  (p<0.001).	  	  	  








	   There	  was	  no	  difference	  among	  groups	  in	  complication	  incidence	  (p=0.9)	  or	  in	  the	  number	  of	  cats	  with	  complications	  that	  survived	  to	  discharge.	  (Table	  7).	  Eight	  PA	  cats	  (11%),	  9	  control-­‐FNA	  cats	  (14%)	  and	  5	  control-­‐no	  FNA	  cats	  (8%)	  developed	  complications	   within	   48-­‐hours	   of	   their	   pancreatic	   aspirate	   procedure.	  Complications	   occurred	   in	   7/62	   PA	   cats	   that	   had	   the	   pancreas	   and	   other	   tissues	  sampled	  (three	  liver,	  three	  peritoneal	  effusion,	  and	  one	  both),	  and	  in	  1/11	  that	  had	  only	  pancreatic	  aspiration.	  Two	  PA	  cats,	  one	  Control-­‐FNA	  cat	  and	  2	  Control-­‐no	  FNA	  cats	   had	   recheck	   ultrasounds	   while	   hospitalized	   to	   evaluate	   for	   complications.	  Overall,	   3/8	   (37%)	   of	   the	   PA	   cats	   and	   5/9	   (56%)	   of	   the	   Control-­‐FNA	   cats	  experiencing	  complications	  survived	  to	  discharge	  compared	  with	  57/65	  (88%)	  and	  49/54	   	   (91%),	   respectively,	   without	   clinical	   complications.	   There	   was	   a	   40%	  survival	  rate	  (2/5)	  in	  the	  Control-­‐No	  FNA	  cats	  developing	  complications	  after	  their	  ultrasounds	  compared	  with	  48/56	  (86%)	  without	  complications.	  	  
Discussion:	  	  	   This	   study	   failed	   to	   demonstrate	   any	   increase	   in	   complication	   or	  mortality	  rates	  in	  cats	  undergoing	  pancreatic	  aspiration	  compared	  to	  those	  who	  did	  not.	  The	  incidence	   of	   complications	   in	   our	   study	   for	   cats	   undergoing	   FNA	   of	   any	   intra-­‐abdominal	   organ	   is	   higher	   than	   that	   in	   one	   previous	   report	   of	   about	   5%67.	   We	  evaluated	  changes	   in	  clinical	   status	  up	   to	  48	  hours	  post-­‐ultrasound	   to	  ensure	   that	  we	  accounted	  for	  all	  potential	  complications.	  Many	  of	   the	  complications	  we	  report	  are	  unlikely	  to	  be	  due	  to	  the	  aspiration	  procedure.	  This	  is	  supported	  by	  the	  lack	  of	  difference	   in	   complication	   rate	   experienced	   by	   cats	   that	   did	   or	   did	   not	   have	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aspiration	   procedure(s)	   performed.	   The	   majority	   of	   complications	   in	   the	   PA	   cats	  were	   noted	   when	   a	   second	   organ,	   typically	   the	   liver,	   was	   aspirated.	   The	   major	  complications	   encountered	   in	   PA	   and	   Control-­‐FNA	   cats	   were	   hemorrhage	   and	  hypotension,	  which	  together	  occurred	  in	  3%	  (PA	  cats)	  and	  6%	  (Control-­‐FNA)	  of	  the	  cats.	  	  	   The	  Control-­‐No	  FNA	  cats	  were	  more	   likely	  to	  be	  hospitalized	  in	  the	  general	  wards	  than	  the	  ICU,	  which	  suggests	  that	  they	  may	  not	  have	  been	  as	  critically	   ill	  as	  the	   cats	   in	   the	   other	   groups.	  We	   attempted	   to	  match	   for	   hospitalization	   between	  groups,	  but	  due	  to	  the	  numerous	  matching	  criteria	  this	  was	  difficult.	  However,	  their	  complication	  rate	  was	  not	  different	  from	  the	  rate	  of	  the	  other	  groups.	  This	  supports	  that	  the	  complication	  risk	  is	  not	  greater	  for	  more	  critically	  ill	  cats.	  	  	   The	   Control-­‐FNA	   group	   cats	   had	   higher	   serum	   bilirubin	   concentrations	  relative	  to	  the	  other	  groups	  of	  cats.	  This	  may	  reflect	  a	  propensity	  for	  this	  group	  of	  cats	   to	   have	   primary	   hepatic	   or	   biliary	   pathology,	   likely	   resulting	   in	   a	   decision	   to	  aspirate	   the	   liver	   rather	   than	   the	   pancreas,	   despite	   ultrasonographic	   pancreatic	  abnormalities.	   PA	   cats	   had	   a	   higher	   proportion	   of	   pancreatic	   nodules	   which	  may	  have	   led	   to	   clinician	   bias	   towards	   aspirating	   the	   pancreas	   due	   to	   suspicion	   of	  neoplasia.	   One	   previous	   study	   demonstrated	   overlap	   in	   ultrasonographic	  abnormalities	   between	   cats	   with	   pancreatic	   neoplasia	   and	   nodular	   hyperplasia67.	  	  Due	  to	  the	  high	  variability	  in	  ultrasonographic	  findings	  and	  the	  small	  number	  of	  cats	  in	  each	  cytologic	  category,	  we	  did	  not	  attempt	  to	  correlate	  ultrasound	  findings	  with	  cytologic	  appearance.	  	  
 55 
 
	   The	  pancreatic	  cytologic	  recovery	  rate	  of	  67%	  is	  similar	  to	  the	  86%	  recovery	  that	  is	  reported	  for	  aspiration	  of	  abdominal	  masses	  in	  dogs	  and	  cats.73	  In	  the	  current	  study,	   samples	  were	  diagnostically	  useful	   in	  cases	  of	  various	   forms	  of	  pancreatitis	  (n=21),	  neoplasia	  (n=14),	  and	  septic	  abscessation	  (n=1).	  There	  was	  good	  correlation	  with	   histopathology	   in	   the	   small	   number	   of	   cases	   available	   for	   comparison,	  consistent	   with	   reports	   that	   specificity	   for	   cytology	   is	   generally	   very	   good.15,16.	  Negative	   results	   may	   not	   be	   accurate,	   as	   the	   distribution	   of	   lesions	   within	   the	  pancreas	   is	   known	   to	   be	  multifocal74.	   	   It	   is	   interesting	   that	   although	   the	   cyologic	  yield	  was	  not	  typically	  fair-­‐excellent,	  it	  still	  had	  a	  fairly	  good	  recovery	  rate.	  	  	   There	  are	  several	  limitations	  to	  this	  study.	  As	  a	  retrospective	  study,	  we	  were	  unable	  to	  control	  for	  variations	  in	  clinician	  bias	  for	  or	  against	  pancreatic	  aspiration,	  clinical	  pathologist	  and	  radiologist	   interpretation,	   radiologist	  aspiration	   technique,	  and	  client	  permission	  for	  FNA	  to	  be	  performed.	  Ideally,	  each	  PA	  cat	  would	  have	  been	  matched	   to	   one	   cat	   from	   each	   control	   group;	   this	   was	   not	   possible	   based	   on	   the	  multiple	  matching	  criteria	  established.	  There	  was	  also	  some	  variation	   in	  matching	  by	  ultrasound	  lesions,	  since	  each	  cat	  had	  multiple	  lesions	  and	  it	  was	  not	  possible	  to	  match	  on	  all	  of	  them.	  	  	   The	   largest	  challenge	   in	  this	  study	  that	  was	  encountered	  was	  the	  matching.	  The	  matching,	  as	  it	  involved	  multiple	  criteria	  as	  far	  the	  cats	  were	  concerned	  (time	  of	  admission,	   location	  of	   hospitalization,	   age	   group,	   etc),	   as	  well	   as	   ultrasonographic	  findings,	   made	   it	   difficult	   to	   match	   the	   cats	   perfectly.	   The	   interpretations	   of	   the	  ultrasound	   findings	   varied	   based	   on	   the	   radiologist,	   and	   there	   were	   many	  ultrasound	  findings	  to	  match	  the	  cases	  and	  controls	  by.	  This	  resulted	  in	  preferential	  
 56 
 
matching	   by	   certain	   criteria	   (pancreas	   size,	   echotexture,	   margin)	   before	   other	  findings	  (masses,	  peritoneal	  effusion).	  These	  issues	  likely	  introduced	  variability	  into	  the	  groups.	  	  	   Another	   issue	   that	  was	   encountered	  was	   the	   grouping	   of	   the	   cats.	   Initially,	  there	   were	   two	   groups	   in	   the	   study	   design:	   a	   Case	   group	   and	   a	   Control	   group.	  However,	  after	  matching	  was	  performed,	  it	  was	  realized	  that	  the	  controls	  needed	  to	  be	  split	  into	  two	  groups:	  those	  who	  had	  had	  aspirates	  (Control-­‐FNA)	  and	  those	  who	  had	  not	  (Control-­‐No	  FNA).	  This	  made	  matching	  of	  the	  cats	  imperfect,	  as	  there	  were	  some	  Case	  cats	  who	  were	  matched	  with	  two	  controls	  from	  one	  specific	  group.	  	  	  	   Our	   data	   support	   previous	   smaller	   studies	   demonstrating	   that	   ultrasound-­‐guided	   aspiration	   of	   the	   feline	   pancreas	   is	   a	   safe	   diagnostic	   procedure.	   The	  combination	  of	  acceptable	  risk	  and	  good	  diagnostic	  yield,	  with	  initial	  indications	  of	  good	   correlation	   with	   histopathology,	   suggests	   that	   pancreatic	   cytology	   can	   be	   a	  safe	  and	  valuable	  tool	  in	  the	  diagnosis	  of	  feline	  pancreatic	  disease.	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Tables	  	  	   LDA	  Group	   IAD	  Group	   P-­‐value	  Age	  (years)	   5.7	   6.4	   0.55	  BUN	  (9-­‐31	  mg/dl)	   33.2	   24.7	   0.16	  Total	  Bilirubin	  (0-­‐0.3	  mg/dl)	   6.1	   1.4	   0.1	  ALP	  (8-­‐139	  u/l)	   333.8	   246.3	   0.88	  PT	  (6.2-­‐7.7	  sec)	   7.8	   7.4	   0.15	  aPTT	  (9.8-­‐14.6	  sec)	   13.6	   13.5	   0.93	  Fibrinogen	   0.56	   0.48	   0.26	  ATIII%	   69%	   70%	   0.8	  Bands	  (x1,000/µl)	   0.79	   1.04	   0.43	  
Table	  1:	  Differences	  in	  baseline	  parameters	  between	  two	  treatment	  groups.	  Reference	  range	  for	  each	  parameter	  provided.	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   No	  Thrombosis	   Thrombosis	   P-­‐value	  Age	  (years)	   5.9	   6.5	   0.7	  BUN	  (9-­‐31	  mg/dl)	   14.9	   25.4	   0.04	  Total	  Bilirubin	  (0-­‐0.3	  mg/dl)	   2.3	   8.4	   0.06	  ALP	  (8-­‐139	  u/l)	   302.2	   270.5	   0.6	  PT	  (6.2-­‐7.7	  sec)	   7.5	   7.7	   0.6	  aPTT	  (9.8-­‐14.6	  sec)	   13	   14.9	   0.04	  Fibrinogen	   0.48	   0.6	   0.3	  ATIII%	   68%	   72%	   0.8	  Bands	  (x1,000/µl)	   0.87	   1.0	   0.4	  LDA	   14	   8	  Treatment	  Group	   IAD	   16	   2	   0.07	  
Table	  2:	  Differences	  in	  the	  baseline	  variables,	  and	  number	  of	  dogs	  in	  each	  treatment	  group,	  between	  the	  dogs	  with	  confirmed/suspected	  or	  no	  evidence	  of	  thromboembolism.	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Table	  3:	  Distribution	  of	  cats	  in	  each	  group	  in	  terms	  of	  location	  of	  hospitalization	  (ICU	  vs	  general	  wards),	  discharge	  status,	  and	  pre-­‐ultrasound	  chemistry	  values	  expressed	  as	  median	  (95%	  Confidence	  Interval	  for	  the	  mean)	  in	  each	  group.	  *Control-­‐No	  FNA	  cats	  were	  more	  likely	  to	  be	  hospitalized	  in	  the	  wards	  than	  in	  the	  





(n=61)	  General	  Wards	   47	  	  (64%)	   28	  (44%)	   46	  (75%)*	  Hospitalization	  
ICU	   26	  (36%)	   35(56%)	   15	  (25%)	  0-­‐8	  years	   10	  (14%)	   14	  (22%)	   21	  (35%)	  9-­‐15	  years	   39	  (53%)	   42	  (67%)	   30	  (49%)	  
Age	  Group	  
>16	  years	   24	  (33%)	   7	  (11%)	   10	  (16%)	  Neutered	  Male	   45	  (62%)	   43	  (68%)	   32	  (52%)	  Sex	   Spayed	  Female	   28	  (38%)	   20	  (32%)	   29	  (48%)	  	  Alive	   	  60	  (82%)	   	  53	  (84%)	   	  51	  (83%)	  Euthanized	   10	  (17%)	   8	  (13%)	   7	  (12%)	  
	  
Discharge	  Status	  
Died	   1	  (1%)	   2	  (3%)	   3	  (5%)	  ALP	  (U/L)	   30	  (61-­‐275)	   31	  (63-­‐230)	   34	  (44-­‐110)	  ALT	  (U/L)	   94	  (157-­‐423)	   92	  (114-­‐312)	   75	  (77-­‐214)	  GGT	  (U/L)	   3	  (2.8-­‐7.8)	   3	  (2.8-­‐5.2)	   3	  (3.1-­‐8.8)	  Bilirubin(mg/dL)	   0.3	  (1.4-­‐4.6)	   3	  (2.8-­‐5.2)**	   0.4	  (1.4-­‐5.3)	  
Biochemistry	  
Results	  
Creatinine(mg/dL)	   1.8	  (1.6-­‐2.9)	   1.5	  (1.5-­‐2.9)	   1.75	  (2.2-­‐4.3)	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ICU	  (p<0.001).	  There	  was	  no	  significant	  difference	  in	  the	  discharge	  status	  among	  cats.	  **Control-­‐FNA	  cats	  had	  a	  higher	  total	  bilirubin	  compared	  to	  the	  other	  two	  groups	  (P<0.001).	  	  	  	  Ultrasonographic	  Finding	   PA	  Cats	  (n=73)	   Control-­‐FNA	  (n=63)	   Control-­‐No	  FNA	  (n=61)	  Enlarged	  Pancreas	   27	  (40%)	   26	  (41%)	   22	  (36%)	  Irregular	  Pancreas	   28	  (38%)	   21	  (33%)	   25	  (40%)	  Hypoechoic	  Pancreas	   34	  (46.5%)	   34	  (54%)	   37	  (61%)	  Peritoneal	  Effusion	   33	  (45%)	   22	  (35%)	   17	  (28%)	  Pancreatic	  Masses/Nodules	   33	  (45%)*	   16	  (25%)	   11	  (18%)	  
Table	  4:	  Prevalence	  of	  the	  most	  common	  ultrasonographic	  abnormalities	  among	  cats	  within	  each	  study	  group.	  *PA	  cats	  were	  significantly	  more	  likely	  to	  have	  mass	  lesions	  or	  nodular	  change	  to	  their	  pancreas	  (p<0.01).	  	  	  	  	  Category	  of	  Pathology	   Number	  of	  Cats	  Suppurative	   14	  (1	  septic)	  Inflammation	   Lymphocytic	   7	  Cyst	   	   3	  Necrosis	   	   11	  Hyperplasia	   	   6	  Carcinoma	   11	  Round	  Cell	  	   2	  Neoplasia	   Unknown	   1	  No	  Abnormalities	   	   11	  Inconclusive	   	   24	  
Table	  5:	  Distribution	  of	  pathologic	  diagnoses	  from	  PA	  cats.	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   Cytology	  Results	   Histopathology	  Results	  Mild	  increase	  in	  plasma	  cells	  and	  lymphocytes	   No	  significant	  microscopic	  lesions	  Carcinoma	  (n=2)	   Carcinoma	  (n=2)	  Suggestive	  for	  carcinoma	   Carcinoma	  Lymphocytic	  inflammation	   Lymphocytic	  and	  plasmacytic	  inflammation	  Lymphocytic	  inflammation	  (n=2)	   Lymphocytic	  and	  plasmacytic	  inflammation	  with	  fibrosis	  (n=2)	  Nondiagnostic	  (n=2)	   Amyloidosis	  (n=2)	  
Table	  6:	  Correlation	  between	  FNA	  pancreatic	  samples	  and	  pancreatic	  histopathology.	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   Complication	   PA	  Cats	  (n=73)	   Control-­‐FNA	  (n=63)	   Control-­‐No	  FNA	  (n=61)	  Hypotension	   1	   3	   1	  
Respiratory	  Distress	   3	   0	   0	  Hemoabdomen	   1	   1	   0	  Whole	  Blood	   1	   0	   0	  Packed	  Red	  Blood	  Cells	   2	   3	   2	  Fresh	  Frozen	  Plasma	   2	   0	   2	  Oxyglobini	   0	   1	   0	  Pleural	  Effusion	   0	   1	   0	  Total	  Complications	   10*	   9	   5	  Survival	  in	  cats	  with	  complications	  (%)	   3	  (37%)	   5	  (56%)	   2	  (40%)	  *10	  complications	  occurred	  in	  8	  cats.	  One	  cat	  in	  this	  group	  experienced	  hypotension	  and	  received	  whole	  blood,	  and	  a	  second	  cat	  developed	  hemoabdomen	  and	  received	  a	  packed	  red	  blood	  cell	  transfusion.	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